

# Assurance Case Report

generated on 02.06.2014 at 13:34

by Brian Larson (blarson)

on server: tct.nor-sta.eu

Project name: **Open PCA Pump Assurance Case**

Folder: **pcapac**

## Project description:

This assurance case was created to be part of exemplary medical device design artifacts, demonstrating application of best practices by Kansas State University for the US Food and Drug Administration's Scholar-in-Residence program through the National Science Foundation (#0932289, #1239543). As such, this assurance case links to the other artifacts, requirements and design.

This work is protected under the Creative Commons Attribution-Share Alike license:  
<http://creativecommons.org/licenses/by-sa/3.0>

## List of sections:

1. Open PCA Pump Assurance Case
2. An argument that Kansas State University's Open PCA Pump design is both acceptably safe and effective
3. Background Information
4. 'Major' Level of Concern
5. PCA Pump is Major Level of Concern as defined by FDA
6. External Infusion Pumps are FDA Class II Devices
7. Claim 0: PCA pump is effective in its medical function and is acceptably safe
8. Claim 1: PCA pump is effective
9. Claim 1.1: PCA pump performs intended function
10. Claim 1.1.1: Combination of individual behaviors is the intended function
11. Requirements Reference
12. Claim 1.1.2: PCA Pump infuses at basal rate
13. Claim 1.1.3: Upon pressing of Patient Button, a VTBI will be infused quickly, returning to basal rate
14. Claim 1.1.4: Clinician may command VTBI to be infused over a specified period of time
15. Claim 1.1.5: Pressing Stop Button stops pumping
16. Claim 1.1.6: Upon detection of minor hazards, pump at KVO rate

17. Claim 1.1.7: Upon detection of critical hazards, stop pumping
18. Claim 1.2: Effectiveness of intended function demonstrated in clinical trials
19. Claim 2: PCA pump is acceptably safe
20. Claim 2.1: All hazards have been identified
21. Claim 2.2: All identified hazards have been mitigated
22. Rationale 2.2: Mitigation of each hazard adds confidence of safety
23. Claim 2.2.A: Operational hazards have been mitigated
24. Table 1 – Operational Hazard Examples
25. Claim 2.2.A.1: Air in Line hazard has been mitigated
26. Claim 2.2.A.1.1: Pump stopped when Internal air in line is detected
27. Verification of mitigation
28. Claim 2.2.A.1.2: Clinician training mitigates external sources of air in line
29. Claim 2.2.A.2: Occlusion hazard has been mitigated
30. Claim 2.2.A.2.1: Occlusion is detected by up- and down-stream monitors
31. Verification of mitigation
32. Claim 2.2.A.2.2: Pump stops
33. Verification of mitigation
34. Claim 2.2.A.3: Free flow hazard has been mitigated
35. Verification of Mitigation
36. Claim 2.2.A.4: Reverse flow hazard has been mitigated
37. Verification of Mitigation
38. Claim 2.2.A.5: Too many user boluses hazard has been mitigated
39. Claim 2.2.A.6: Uneven delivery hazard has been mitigated
40. Claim 2.2.A.7: Drug leakage hazard has been mitigated
41. Claim 2.2.A.8: Incorrect flow rate hazard has been mitigated
42. Claim 2.2.B: Environmental hazards have been mitigated
43. Table 2 – Environmental Hazard Examples
44. Claim 2.2.B.1: Failure to Operate due to Environment Mitigated
45. Claim 2.2.B.2: Pump Exposed to Pathogens, Allergens, Hazardous Substances Mitigated
46. Claim 2.2.B.3: Tampering mitigated
47. Claim 2.2.B.3.1: Unauthorized tampering of pump settings mitigated
48. Claim 2.2.B.3.2: Panel lock broken mitigated by having strong lock and case
49. Claim 2.2.B.3.3: Panel/door opened during infusion mitigated by strong lock and case
50. Claim 2.2.B.3.4: Infusion cannot be started with open door
51. Claim 2.2.B.4: Non-human Interference mitigated

52. Claim 2.2.B.4.1: Electromagnetic Interference Mitigated by Shielding of Case
53. Claim 2.2.B.4.2: Electrostatic discharge mitigated by touch-screen and case design
54. Claim 2.2.B.4.3: Interference from power mitigated by ferrite filter
55. Claim 2.2.C: Electrical hazards have been mitigated
56. Table 3 – Electrical Hazard Examples
57. Claim 2.2.C.1: Power supply overheating mitigated by shutting down if temperature gets too high
58. Claim 2.2.C.2: Backup Battery Charge Fault Mitigated by Detection and Reporting
59. Claim 2.2.C.3: Supply voltage error mitigated by monitoring and reporting
60. Claim 2.2.C.4: Battery failure mitigated by detection and reporting
61. Claim 2.2.C.5: Leakage current mitigated by isolating mains power
62. Claim 2.2.C.6: Power supply circuit failure mitigated by detection and shut off
63. Claim 2.2.C.7: EMI from pump mitigated by design
64. Claim 2.2.D: Hardware hazards have been mitigated
65. Table 4 – Hardware Hazard Examples
66. Claim 2.2.D.1: System Failure Mitigated by Safety Architecture
67. Claim 2.2.D.2: Network error mitigated by switching to stand-alone mode
68. Claim 2.2.D.3: Memory failure mitigated by error correction
69. Claim 2.2.D.4: False alarms are not hazards
70. Claim 2.2.D.5: Missed alarm due to sensor failure mitigated by safety architecture
71. Claim 2.2.D.6: Incorrect dose mitigated by Rx on label, authenticated
72. Claim 2.2.E: Software hazards have been mitigated
73. Table 5 – Software Hazard Examples
74. Claim 2.2.E.1: Data errors in event and fault logs are mitigated by fault masking and sending event reports to ICE as they occur
75. Claim 2.2.E.2: Software runtime errors mitigated by proving program correctness and avoiding problematic software functions
76. Claim 2.2.E.3: Corrupted Infusion Commands mitigated by limiting their possible function
77. Claim 2.2.E.4: Pump could not be silenced by alarm inactivation
78. Claim 2.2.E.5: Incorrect Software mitigated by version control
79. Claim 2.2.E.6: Incorrect drug library loaded mitigated by authentication
80. Claim 2.2.E.7: Failure to install software updates mitigated by manufacturer and hospital process
81. Claim 2.2.F: Mechanical hazards have been mitigated
82. Table 6 – Mechanical Hazard Examples
83. Claim 2.2.F.1: Unable to set dose mitigated by scanning Rx from label
84. Claim 2.2.F.2: Failure to alarm by broken speaker mitigated by alarm through ICE and

audible test

85. Claim 2.2.F.3: Broken power cord mitigated by electrocuting users
86. Claim 2.2.F.4: Pump motor failure mitigated by alarm upon pump stopping
87. Claim 2.2.G: Biological and chemical hazards have been mitigated
88. Table 7 – Biological and Chemical Hazard Examples
89. Claim 2.2.H: Use hazards have been mitigated
90. Table 8 – Use Hazard Examples
91. Claim 2.2.H.1: The hazard of user not understanding how to initiate pump operation is mitigated by clinician authentication and training
92. Claim 2.2.H.2: Incorrect prescription mitigated by prescription authentication
93. Claim 2.2.H.3: The hazard that infusion is stopped prematurely can only be mitigated by proper procedure
94. Claim 2.2.H.4: The hazard that the user fails to detect notifications is mitigated
95. Claim 2.2.H.4.1: Alarm fatigue is avoided by only raising necessary alarms
96. Claim 2.2.H.4.2: Background noise will not cause user(s) to fail to detect notification(s)
97. Claim 2.2.H.5: The wrong drug hazard has been mitigated by authenticating Rx.
98. Claim 2.2.H.6: Physical set up is correct
99. Claim 2.2.H.7: Users cannot "work around" or "bypass" software limits on drug/dose parameters
100. Claim 2.2.H.8: The hazard that clinicians ignore warnings and alarms is mitigated
101. Claim 2.2.H.8.1: False alarms/warnings are minimized to reduce alarm fatigue
102. Claim 2.2.H.9: Clinicians do not misinterpret alarms/warnings
103. Claim 2.2.H.9.1: Standard symbols and sounds reduce misinterpretation
104. Claim 2.2.H.9.2: Messages are meaningful and unambiguous
105. Claim 2.2.H.10: Users understand pump status and operational modes
106. Claim 2.2.H.12: The self over-medication hazard has been mitigated by requiring a minimum time between patient boluses.
107. Claim 2.2.H.13: The clinician follows instructions to disconnect the pump
108. Claim 2.2.H.14: The hazard of giving the drug to the wrong patient has been mitigated by patient authentication.
109. Claim 2.2.H.15: The use by unauthorized persons hazard has been mitigated by clinician authentication.
110. Device Hazard Analysis Guidance By FDA
111. Claim 2.3: Risk analysis shows fewer than one death or permanent injury in a million hours of operation due to malfunction
112. Claim 2.4: Software correctly performs intended function
113. Claim 2.4.1: Software specification reflects requirements (validation)
114. Claim 2.4.2: Software conforms to its specification (verification)

- 115. Evidence
  - 116. System Feature Tests
  - 117. Correctness Proofs
  - 118. Clinical Trials
  - 119. Standards and FDA Guidance
  - 120. Architecture
- Index of assurance case components

# 1. Open PCA Pump Assurance Case




**i** **Open PCA Pump Assurance Case**

**i** **An argument that Kansas State University's Open PCA Pump design is both acceptably safe and effective**

*See details in section 2*

## 2. An argument that Kansas State University's Open PCA Pump design is both acceptably safe and effective



### An argument that Kansas State University's Open PCA Pump design is both acceptably safe and effective

This Open PCA Pump assurance case is an exemplary medical device design artifact created as part of the NSF/FDA Scholar in Residence program. It is intended to show a convincing argument that would be part of a submission for FDA medical device approval.

An assurance case should be developed concurrently with device design, starting at the beginning of the project by engineers, not thrown together by Regulatory Affairs during submission preparation.

This assurance case should be considered to be mid-project, necessarily incomplete, with placeholders for test reports and clinical trials. An actual assurance case would continue to be refined and expanded until complete, with references to all the reports and data needed to support asserted facts and claims.

Ideally preparation of an assurance case would be the responsibility of a seasoned, experienced system engineer, with contributions from the entire engineering team with contributions from marketing, regulatory affairs, research, clinical trials, and potential users. Tracing of the argument down to facts from requirements, architecture, verification and validation will be superb training for novice engineers.



### Subject of Assurance Case: PCA Pump

The scope of this Open PCA Pump Assurance Case is a hypothetical patient-controlled analgesia pump, its requirements developed according to FAA's Requirements Engineering Management Handbook, and its architectural model in the Architecture Analysis and Design Language.



## **Requirements: Draft 0.11**

**Evidence:** ICE-PCArequirements.pdf

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

**Link(s) to this node in section(s):**

Section 11. Requirements Reference



## **Background Information**

*See details in section 3*



## **'Major' Level of Concern**

*See details in section 4*



## **External Infusion Pumps are FDA Class II Devices**

*See details in section 6*



## **Claim 0: PCA pump is effective in its medical function and is acceptably safe**

*See details in section 7*




## **Evidence**

*See details in section 115*



### 3. Background Information



#### Background Information

#### TRUST-IT assurance case notation

Basics of TRUST-IT notation are explained in attached document.

*[note: how you can get the document?*

1) select the "Evidence" bar below

2) click the "Open Evidence" button

A short summary of NOR-STA/TRUST-IT notation will open a .pdf in another tab of your browser.

]

**Evidence:** TRUST-IT notation.pdf

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

#### Conventions

All references placed under "Evidence" information node. Then multiple parts of the assurance case can reference the same evidence.

#### Abbreviations

AADL - Architecture Analysis and Design Language

BLESS - Behavior Language for Embedded Systems with Software

FHA - Functional Hazard Assessment

FMEA - Failure Modes and Effects Analysis

FTA - Fault Tree Analysis

KVO - Keep Vein Open (rate)

OSATE - Open-Source AADL Tool Environment

PCA - Patient-Controlled Analgesic (pump)

RDAL - Requirements Definition and Analysis Language

SFT - System Feature Test

VTBI - Volume To Be Infused



## **'Wet' Safety vs. 'Dry' Safety**


'Wet' safety concerns improper use. 'Dry' safety concerns the device itself. Achieving safety in practice requires both, but the skills necessary are vastly different.

Wet safety involves human factors and institutional processes that are necessarily subjective. Dry safety can be definitively engineered.

Whenever possible, wet safety hazards should be mitigated by dry safety means. For the Open PCA Pump, hazards due to improper prescription entry are mitigated by reading the prescription from the drug container with a scanner, followed by authentication. Similarly, clinician authorization is enforced by authenticating clinician badges, but the hospital itself must assure that those so authorized are indeed capable, competent, and trained.

Nevertheless, engineered dry safety can never overcome all wet safety hazards. Those think they're being revelatory in pointing this out become tedious and annoying.

## 4. 'Major' Level of Concern



### 'Major' Level of Concern



#### Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices

**Evidence:** FDAHazardAnalysis.pdf#page=8


**Repository:** NOR-STA SVN PCAPAC - NOR-STA



#### PCA Pump is Major Level of Concern as defined by FDA

*See details in section 5*

## 5. PCA Pump is Major Level of Concern as defined by FDA




 **PCA Pump is Major Level of Concern as defined by FDA**

 **Apply criteria in Tables 1 & 2 of FDA Guidance**

 **2. Is the Software Device intended to be used in combination with a drug or biologic? Yes.**

Second question of Table 1 in FDA Guidance

## 6. External Infusion Pumps are FDA Class II Devices



### External Infusion Pumps are FDA Class II Devices

1.

19 § 880.5725 Infusion pump

2.

20 (a) Identification. An infusion pump is a device used in a health care facility to pump fluids

3.

21 into a patient in a controlled manner. The device may use a piston pump, a roller pump, or

4.

22 a peristaltic pump and may be powered electrically or mechanically. The device may also

5.

23 operate using a constant force to propel the fluid through a narrow tube which determines

6.

24 the flow rate. The device may include means to detect a fault condition, such as air in, or

7.

25 blockage of, the infusion line and to activate an alarm.

8.

26 (b) Classification. Class II (performance standards).




## **21 CFR 880.5725**

**Evidence:** IPGenera Guidance.pdf#page=5

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 7. Claim 0: PCA pump is effective in its medical function and is acceptably safe



### **Claim 0: PCA pump is effective in its medical function and is acceptably safe**

This is the principal claim of the assurance case. It corresponds to evaluation criteria of medical devices used by US Food and Drug Administration to determine approval.



### **Strategy 0: Argue for safety and effectiveness separately, but coordinated**



### **Rationale 0: No medical device can be completely safety; its benefit must justify its risk**

If you had an ailment that kills 99% of those diagnosed within a year, a drug or device that kills half of those who get it, but extends normal mortality for five years for the others, will be justified.

A PCA pump cures nothing. It merely reduces the pain caused by something else. As such, the acceptable risk of using a PCA pump is very low, but not zero.

Therefore, PCA pump must be exceptionally safe, chasing down and mitigating every possible hazard



**Claim 1: PCA pump is effective**

*See details in section 8*




**Claim 2: PCA pump is acceptably safe**

*See details in section 19*



## 8. Claim 1: PCA pump is effective



 **Claim 1: PCA pump is effective**

 **Strategy 1: PCA pump performs intended function which has been clinically verified**

 **Rationale 1: PCA pump must perform intended function; that function must be medically effective**

 **Intended function defined in requirements document**


 **Claim 1.1: PCA pump performs intended function**

*See details in section 9*

 **Claim 1.2: Effectiveness of intended function demonstrated in clinical trials**

*See details in section 18*

## 9. Claim 1.1: PCA pump performs intended function



### Claim 1.1: PCA pump performs intended function

### Argue over all behaviors, that they are performed correctly, and their composition is the intended function

### Divide into individual behaviors, and then argue their composition has intended function

### Individual behaviors, and intended function, as defined in Requirements

### Claim 1.1.1: Combination of individual behaviors is the intended function

*See details in section 10*

### Claim 1.1.2: PCA Pump infuses at basal rate

*See details in section 12*



**Claim 1.1.3: Upon pressing of Patient Button, a VTBI will be infused quickly, returning to basal rate**

*See details in section 13*



**Claim 1.1.4: Clinician may command VTBI to be infused over a specified period of time**

*See details in section 14*



**Claim 1.1.5: Pressing Stop Button stops pumping**

*See details in section 15*



**Claim 1.1.6: Upon detection of minor hazards, pump at KVO rate**

*See details in section 16*




**Claim 1.1.7: Upon detection of critical hazards, stop pumping**

*See details in section 17*



**Many other intended functions, left to reader to add to assurance case**

## 10. Claim 1.1.1: Combination of individual behaviors is the intended function



### Claim 1.1.1: Combination of individual behaviors is the intended function

This is combination of features, not components. For the PCA pump,

- pump drug at prescribed rate
- give extra bolus upon patient request, except if possibly unsafe
- authenticate patient, prescription, and attending clinician (the operator)
- display current pump rate
- allow clinician to administer extra bolus upon discretion, except if possibly unsafe



### Strategy 1.1.1: Claimed behaviors are traced to Requirements

The Requirements defines the "intended function" for the PCA pump.

All this says is that, all the claims following (1.1.2 to 1.1.7+) trace to Requirements. Therefore the behaviors claimed are indeed the intended function of the PCA pump



**Rationale 1.1.1: Requirement define intended function, tracing behavior to requirements shows it's part of the intended function**




**The Requirements define intended function**



**Requirements Reference**

*See details in section 11*

## 11. Requirements Reference




### Requirements Reference

### (Requirements) Draft 0.11

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

Link to description in section: 2

## 12. Claim 1.1.2: PCA Pump infuses at basal rate



### Claim 1.1.2: PCA Pump infuses at basal rate

When properly programmed, by authenticated clinician.  
Background (normal) rate of infusion.

### Strategy 1.1.2: Trace to Requirement and System Feature Test

### Rationale 1.1.2: SFT is direct confirmation of behavior defined in requirement

### Basal Rate Required

### Requirement: R4.1.0(1) Basal Flow Rate

**Evidence:** ICE-PCArequirements.pdf#nameddest=basal flow rate

**Repository:** NOR-STA SVN PCAPAC - NOR-STA


 **Basal Rate System Feature Test Report**

 **() Basal Rate SFT**

Link to description in section: 116



### 13. Claim 1.1.3: Upon pressing of Patient Button, a VTBI will be infused quickly, returning to basal rate



#### **Claim 1.1.3: Upon pressing of Patient Button, a VTBI will be infused quickly, returning to basal rate**

This is the main function. There are all sorts of safety limitations, but here we're arguing that it performs its normal function.



#### **Strategy 1.1.3: Trace to Requirement and System Feature Test**



#### **Rationale 1.1.3: SFT is direct confirmation of behavior defined in requirement**



#### **Patient-Bolus Request Required**



## **Requirement: R4.2.0(1) Patient-Requested Bolus**

**Evidence:** ICE-PCArequirements.pdf#nameddest=patient-requested bolus

**Repository:** NOR-STA SVN PCAPAC - NOR-STA




## **Patient-Bolus Request System Feature Test Report**



## **() Patient-Bolus Request SFT**

Link to description in section: 116

## 14. Claim 1.1.4: Clinician may command VTBI to be infused over a specified period of time



 **Claim 1.1.4: Clinician may command VTBI to be infused over a specified period of time**

 **Strategy 1.1.4: Trace to Requirement and System Feature Test**

 **Rationale 1.1.4: SFT is direct confirmation of behavior defined in requirement**

 **Clinician-Requested Bolus Required**

 **Requirement: R4.3.0(2)**

**Evidence:** ICE-PCArequirements.pdf#nameddest=clinician-requested bolus

**Repository:** NOR-STA SVN PCAPAC - NOR-STA




## **Clinician-Requested Bolus System Feature Test Report**



## **() Clinician-Requested Bolus SFT**

Link to description in section: 116

## 15. Claim 1.1.5: Pressing Stop Button stops pumping



 **Claim 1.1.5: Pressing Stop Button stops pumping**

 **Strategy 1.1.5: Trace to Requirement and System Feature Test**

 **Rationale 1.1.5: SFT is direct confirmation of behavior defined in requirement**

 **Stop Button Halts Infusion Required**

 **Requirement: R5.5.0(6) Stop Infusion**

**Evidence:** ICE-PCArequirements.pdf#nameddest=stop%20infusion

**Repository:** NOR-STA SVN PCAPAC - NOR-STA


 **Stop Infusion System Feature Test Report**



## **() Stop Infusion SFT**

Link to description in section: 116

## 16. Claim 1.1.6: Upon detection of minor hazards, pump at KVO rate



### Claim 1.1.6: Upon detection of minor hazards, pump at KVO rate

as specified in Table XX of the Requirements

### Strategy 1.1.6: Trace to Requirement and System Feature Test

### Rationale 1.1.6: SFT is direct confirmation of behavior defined in requirement

### Pump KVO upon minor hazard Required

### Requirement: R4.2.0(6) Alarm Stops Patient-Requested Bolus

**Evidence:** ICE-PCArequirements.pdf#nameddest=alarm stops patient-requested bolus

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Requirement: R4.3.0(4) Alarm Halts Clinician-Requested Bolus**

**Evidence:** ICE-PCArequirements.pdf#nameddest=alarm%20halts%20clinician-requested%20bolus

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Requirement: R4.1.0(4) Alarm Stops Basal Rate**

**Evidence:** ICE-PCArequirements.pdf#nameddest=alarm%20stops%20basal%20rate

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

**Link(s) to this node in section(s):**

Section 17. Claim 1.1.7: Upon detection of critical hazards, stop pumping



### **KVO or Stop on Warning or Alarm System Feature Test Report**




### **() KVO or Stop on Warning or Alarm SFT**

Link to description in section: 116



## 17. Claim 1.1.7: Upon detection of critical hazards, stop pumping



### Claim 1.1.7: Upon detection of critical hazards, stop pumping

as specified in Table XX of the Requirements

### Strategy 1.1.7: Trace to Requirement and System Feature Test

### Rationale 1.1.7: SFT is direct confirmation of behavior defined in requirement

### Stop on Critical Hazard Required

### Requirement: R4.2.0(6) Alarm Stops Patient-Requested Bolus

**Evidence:** ICE-PCArequirements.pdf#nameddest=alarm stops patient-requested bolus

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Requirement: R4.3.0(4) Alarm Halts Clinician-Requested Bolus**

**Evidence:** ICE-PCArequirements.pdf#nameddest=alarm%20halts%20clinician-requested%20bolus

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Requirement: R4.1.0(4) Alarm Stops Basal Rate**

**Evidence:** ICE-PCArequirements.pdf#nameddest=alarm%20stops%20basal%20rate

**Repository:** NOR-STA SVN PCAPAC - NOR-STA




**Patient-Bolus Request System Feature Test Report**




**() Requirement: R4.1.0(4) Alarm Stops Basal Rate**

Link to description in section: 16

## 18. Claim 1.2: Effectiveness of intended function demonstrated in clinical trials



 **Claim 1.2: Effectiveness of intended function demonstrated in clinical trials**

 **Strategy 1.2: Clinical trials must be well designed, well executed, the intended function performed, and results are acceptably safe**

 **Rationale 4: Valid clinical trials must apply the intended function, and show it's acceptably safe**



**() FDA clinical trials law, regulation, and guidance**

Link to description in section: 118



**Clinical trials are well designed**



**() Clinical trial design documents**

Link to description in section: 118



**Clinical trials are well executed**



**() Clinical Trial Report**

Link to description in section: 118



**Clinical trials apply the intended function**



**() Clinical Trial Report**

Link to description in section: 118




**Results of clinical trials show intended function had intended effect**



**() Clinical Trial Report**

Link to description in section: 118

## 19. Claim 2: PCA pump is acceptably safe



### Claim 2: PCA pump is acceptably safe

### Strategy 2: Residule risk of potential hazards after mitigations is acceptable considering the theraputic value of its intended function

### Theraputic value justifies risk

This is the central value question to be answered:  
"Does the patient benefit warrant potential harm?"

The risk, can (potentially) be estimated, but the benefit is inherently subjective. PCA pumps are frequently used in hospice, to alleviate the suffering the last days of terminal illness. Such patients will accept much more risk than patients recovering from minor surgery.

### Subjective argument about the value of pain relief

The subjective argument is unavoidable, must be made, but can be separated from those parts of the assurance case for which objective facts can be ascertained.



## **Used properly by trained clinicians**

FDA guidance for 510(k) approval for infusion pumps was used to guide development of argument that the Open PCA Pump is safe. Many of the hazards identified are errors in use (wet safety), few of which can be addressed by product design (dry safety). Therefore an assertion case about the device itself must assume that it is used according to labeling.



### **Claim 2.1: All hazards have been identified**

*See details in section 20*



### **Claim 2.2: All identified hazards have been mitigated**

*See details in section 21*



### **Claim 2.3: Risk analysis shows fewer than one death or permanent injury in a million hours of operation due to malfunction**


*See details in section 111*



### **Claim 2.4: Software correctly performs intended function**

*See details in section 112*

## 20. Claim 2.1: All hazards have been identified



### Claim 2.1: All hazards have been identified

### Strategy 2.1: Diligent searching by competent professionals for all possible hazards

There can always be hazards, as yet, unknown. Earnestly trying to find all potential hazards is the best anyone can do. The best companies will have process records to show that good people tried to find all hazards.

### Diligent searching by competent professionals is the best that can be done

Of course, hazards can be missed, but that all hazards have been identified must be one of the claims, albeit one that can never be fully assured

### Certification and experience of those performing hazard analysis

List of individual's names, their degrees and relevant training courses, and summary of relevant experience. Some of the team will be novices; others will be experts with long service.



### **Report on process of hazard elicitation**

How was the list of potential hazards compiled?




### **Standards and FDA guidance**

List any external references such as standards or FDA Guidance documents used to identify potential hazards.



## 21. Claim 2.2: All identified hazards have been mitigated



 **Claim 2.2: All identified hazards have been mitigated**

 **Strategy 2.2: Induction over all identified hazards, by class of hazard**

Grouping hazards makes the argument easier to understand

 **Rationale 2.2: Mitigation of each hazard adds confidence of safety**

*See details in section 22*

 **Claim 2.2.A: Operational hazards have been mitigated**

*See details in section 23*

 **Claim 2.2.B: Environmental hazards have been mitigated**

*See details in section 42*

 **Claim 2.2.C: Electrical hazards have been mitigated**

*See details in section 55*

 **Claim 2.2.D: Hardware hazards have been mitigated**

*See details in section 64*



**Claim 2.2.E: Software hazards have been mitigated**

*See details in section 72*



**Claim 2.2.F: Mechanical hazards have been mitigated**

*See details in section 81*



**Claim 2.2.G: Biological and chemical hazards have been mitigated**

*See details in section 87*



**Claim 2.2.H: Use hazards have been mitigated**


*See details in section 89*



**Device Hazard Analysis Guidance By FDA**

*See details in section 110*

## 22. Rationale 2.2: Mitigation of each hazard adds confidence of safety




 **Rationale 2.2: Mitigation of each hazard adds confidence of safety**

 **Untitled argumentation strategy**

 **Untitled rationale**

## 23. Claim 2.2.A: Operational hazards have been mitigated



### **Claim 2.2.A: Operational hazards have been mitigated**

following Table A in guidance

### **Strategy 2.2.A Induction over operational hazards**

### **Rationale 2.2.A: Mitigation of each hazard adds confidence to safety**

### **Table 1 – Operational Hazard Examples**

*See details in section 24*

### **Claim 2.2.A.1: Air in Line hazard has been mitigated**

*See details in section 25*

### **Claim 2.2.A.2: Occlusion hazard has been mitigated**

*See details in section 29*

### **Claim 2.2.A.3: Free flow hazard has been mitigated**

*See details in section 34*

### **Claim 2.2.A.4: Reverse flow hazard has been mitigated**

*See details in section 36*



**Claim 2.2.A.5: Too many user boluses hazard has been mitigated**

*See details in section 38*



**Claim 2.2.A.6: Uneven delivery hazard has been mitigated**

*See details in section 39*



**Claim 2.2.A.7: Drug leakage hazard has been mitigated**


*See details in section 40*



**Claim 2.2.A.8: Incorrect flow rate hazard has been mitigated**

*See details in section 41*

# 24. Table 1 – Operational Hazard Examples




 **Table 1 – Operational Hazard Examples**

 **Table 1 – Operational Hazard Examples**

**Evidence:** IPGenera Guidance.pdf#page=12

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 25. Claim 2.2.A.1: Air in Line hazard has been mitigated



**Claim 2.2.A.1: Air in Line hazard has been mitigated**



**Strategy 2.2.A.1: Argue for mitigation of internal and external causes of air in line separately**



**Rationale 2.2.A.1: Mitigations of external and internal hazards differ**



**Claim 2.2.A.1.1: Pump stopped when Internal air in line is detected**


*See details in section 26*



**Claim 2.2.A.1.2: Clinician training mitigates external sources of air in line**

*See details in section 28*

## 26. Claim 2.2.A.1.1: Pump stopped when Internal air in line is detected



**Claim 2.2.A.1.1: Pump stopped when Internal air in line is detected**



**Strategy 2.2.A.1.1: Stopping pump prevents air in line from entering patient**



**Trace mitigation to requirements, architecture, and verification artifacts**



**Trace mitigation to requirements**



**Reference to requirements for mitigation**

**Evidence:** ICE-PCArequirements.pdf#nameddest=detect air-in-line embolism

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



 **Trace mitigation to architecture**


 **Reference to AADL architecture component**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Verification of mitigation**

*See details in section 27*

## 27. Verification of mitigation



 **Verification of mitigation**

 **Tests and Proof**

 **Each test adds some confidence; proof adds much confidence**

 **Trace mitigation to testing**

 **Reference to test demonstrating mitigation**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Reference to another test demonstrating mitigation**


**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Trace mitigation to software correctness proof**

 **Links to formal specification and proof**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

**28. Claim 2.2.A.1.2: Clinician training mitigates external sources of air in line**



**Claim 2.2.A.1.2: Clinician training mitigates external sources of air in line**

This claim is weak; relies on labeling/training/proper use

**Strategy 2.2.A.1.2: Rely on training because pump cannot detect external air in line**

**Training mitigates external sources of air in line**

**Clinician manual and training ensures sealed delivery path**

**Reference to clinician manual**

Repository: NOR-STA SVN PCAPAC - NOR-STA




**Clinician manual and training ensures compatible infusion set**



**Reference to clinician manual**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 29. Claim 2.2.A.2: Occlusion hazard has been mitigated




 **Claim 2.2.A.2: Occlusion hazard has been mitigated**

 **Strategy 2.2.A.2: Detect occlusion; stop pump**

 **Stopping pump upon occlusion is safe**


 **Claim 2.2.A.2.1: Occlusion is detected by up- and down-stream monitors**

*See details in section 30*

 **Claim 2.2.A.2.2: Pump stops**


*See details in section 32*

### 30. Claim 2.2.A.2.1: Occlusion is detected by up- and down-stream monitors



 **Claim 2.2.A.2.1: Occlusion is detected by up- and down-stream monitors**

 **Occlusion is detected**

 **Trace mitigation to requirements, architecture, and verification artifacts**

 **Trace mitigation to requirements**

 **Reference to requirements for mitigation**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Trace mitigation to architecture**

 **Reference to AADL architecture component**


**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Verification of mitigation**

*See details in section 31*



## 31. Verification of mitigation



 **Verification of mitigation**

 **Tests and Proof**

 **Each test adds some confidence; proof adds much confidence**

 **Trace mitigation to testing**

 **Reference to test demonstrating mitigation**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Reference to another test demonstrating mitigation**


**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Trace mitigation to software correctness proof**

 **Links to formal specification and proof**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 32. Claim 2.2.A.2.2: Pump stops



**Claim 2.2.A.2.2: Pump stops**



**Strategy 2.2.A.2.2: Pump stops when commanded to do so**



**Trace mitigation to requirements, architecture, and verification artifacts**



**Trace mitigation to requirements**



**Reference to requirements for mitigation**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Trace mitigation to architecture**



## Reference to AADL architecture component


**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## Verification of mitigation

*See details in section 33*

### 33. Verification of mitigation



 **Verification of mitigation**

 **Tests and Proof**

 **Each test adds some confidence; proof adds much confidence**

 **Trace mitigation to testing**

 **Reference to test demonstrating mitigation**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Reference to another test demonstrating mitigation**


**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Trace mitigation to software correctness proof**

 **Links to formal specification and proof**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

### 34. Claim 2.2.A.3: Free flow hazard has been mitigated



 **Claim 2.2.A.3: Free flow hazard has been mitigated**

This hazard only occurs in "hanging bag" infusion pumps that don't actually pump, but instead regulate gravity-fed flow.

 **Strategy 2.2.A.3: Show pump is incapable of free-flow**

 **Rely on mechanical design of pumping mechanism**

 **Trace mitigation to requirements**

 **Reference to requirements for mitigation**

Repository: NOR-STA SVN PCAPAC - NOR-STA

 **Trace mitigation to mechanical pump design**

 **Reference to requirements for mitigation**


**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Verification of Mitigation**

*See details in section 35*



## 35. Verification of Mitigation



### Verification of Mitigation

### Tests and mechanical analysis

### Both tests and analysis needed

Because it is impossible to *prove* a negative (no free flow), observation that flow never occurs must be augmented with mechanical engineering analysis.

### No observed free flow

### Attestation no free flow occurs

Repository: NOR-STA SVN PCAPAC - NOR-STA


### Mechanical engineering analysis that free flow is impossible



## **Mechanical analysis**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

### 36. Claim 2.2.A.4: Reverse flow hazard has been mitigated



 **Claim 2.2.A.4: Reverse flow hazard has been mitigated**

 **Strategy 2.2.A.4: Show pump is incapable of reverse flow**

 **Rely on mechanical design of pumping mechanism**

 **Trace mitigation to requirements**

 **Reference to requirements for mitigation**

Repository: NOR-STA SVN PCAPAC - NOR-STA

 **Trace mitigation to mechanical pump design**



## **Reference to requirements for mitigation**


**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **Verification of Mitigation**

*See details in section 37*

## 37. Verification of Mitigation



### Verification of Mitigation

### Tests and mechanical analysis

### Both tests and analysis needed

Because it is impossible to *prove* a negative (no free flow), observation that flow never occurs must be augmented with mechanical engineering analysis.

### No observed reverse flow

### Attestation no reverse flow occurs

Repository: NOR-STA SVN PCAPAC - NOR-STA


### Mechanical engineering analysis that reverse flow is impossible



## **Mechanical analysis**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

### 38. Claim 2.2.A.5: Too many user boluses hazard has been mitigated



 **Claim 2.2.A.5: Too many user boluses hazard has been mitigated**

 **Strategy 2.2.A.5: Show minimum time between patient-requested boluses**

 **Rationale 2.2.A.5: Enforcing minimum time between boluses prevents too many user boluses**

 **Patient bolus will not be delivered until minimum time between boluses has expired**



**Requirement R4.2.0(3): Minimum time between patient-requested bolus**

**Evidence:** ICE-PCArequirements.pdf#nameddest=minimum time between patient-requested bolus

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Architecture: PCA\_Operation\_Threads::Patient\_Bolus\_Checker.imp**

**Evidence:** PCA\_Operation\_Threads.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA




**SFT: Attempt to press patient button before minimum time between boluses expires**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### 39. Claim 2.2.A.6: Uneven delivery hazard has been mitigated




 **Claim 2.2.A.6: Uneven delivery hazard has been mitigated**

 **Strategy 2.2.A.6: Measure drug flow and alarm if measurement differs from intended pump rate by more than allowed tolerance**

 **Rationale 2.2.A.6: Alarming when upon uneven delivery stops flow and hails clinician**

 **Uneven delivery detected and warning or alarm issued**

 **Requirement R5.4.0(2) Basal Over-Infusion Alarm**


**Evidence:** ICE-PCArequirements.pdf#nameddest=basal over-infusion alarm

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Requirement R5.4.0(3) Basal Under-Infusion Warning**

**Evidence:** ICE-PCArequirements.pdf#nameddest=basal under-infusion warning

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Requirement R5.4.0(4) Bolus Over-Infusion Alarm**

**Evidence:** ICE-PCArequirements.pdf#nameddest=bolus over-infusion alarm

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Requirement R5.4.0(5): Bolus Under-Infusion Warning**

**Evidence:** ICE-PCArequirements.pdf#nameddest=bolus under-infusion warning

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Requirement R5.4.0(6): Square Bolus Over-Infusion Alarm**

**Evidence:** ICE-PCArequirements.pdf#nameddest=square bolus over-infusion alarm

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Requirement R5.4.0(7) Square Bolus Under-Infusion Warning**

**Evidence:** ICE-PCArequirements.pdf#nameddest=square bolus under-infusion warning

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Architecture: PCA\_Alarm::Flow\_Rate\_Checker.imp**

**Evidence:** PCA\_Alarm.aadl


**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **SFT: Force variance of flow rate, check if appropriat alarm or warning is railed**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 40. Claim 2.2.A.7: Drug leakage hazard has been mitigated



**Claim 2.2.A.7: Drug leakage hazard has been mitigated**



**Strategy 2.2.A.7: Argue drug leakage minimized by competent mechanical engineering**



**Rationale 2.2.A.7: Mechanical engineers should be able to design pumps that don't leak by now**



**Pump minimizes drug leakage**




**Requirement R6.7.0(1) Minimize Drug Leakage**

**Evidence:** ICE-PCArequirements.pdf#nameddest=minimize drug leakage

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 41. Claim 2.2.A.8: Incorrect flow rate hazard has been mitigated




 **Claim 2.2.A.8: Incorrect flow rate hazard has been mitigated**

 **Strategy 2.2.A.8: Measure drug flow and alarm if measurement differs from intended pump rate by more than allowed tolerance**

 **Rationale 2.2.A.8: Alarming when upon uneven delivery stops flow and hails clinician**

 **Uneven delivery detected and warning or alarm issued**

 **Requirement R5.4.0(2) Basal Over-Infusion Alarm**


**Evidence:** ICE-PCArequirements.pdf#nameddest=basal over-infusion alarm

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Requirement R5.4.0(3) Basal Under-Infusion Warning**

**Evidence:** ICE-PCArequirements.pdf#nameddest=basal under-infusion warning

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Requirement R5.4.0(4) Bolus Over-Infusion Alarm**

**Evidence:** ICE-PCArequirements.pdf#nameddest=bolus over-infusion alarm

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Requirement R5.4.0(5): Bolus Under-Infusion Warning**

**Evidence:** ICE-PCArequirements.pdf#nameddest=bolus under-infusion warning

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Requirement R5.4.0(6): Square Bolus Over-Infusion Alarm**

**Evidence:** ICE-PCArequirements.pdf#nameddest=square bolus over-infusion alarm

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Requirement R5.4.0(7) Square Bolus Under-Infusion Warning**

**Evidence:** ICE-PCArequirements.pdf#nameddest=square bolus under-infusion warning

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Architecture: PCA\_Alarm::Flow\_Rate\_Checker.imp**

**Evidence:** PCA\_Alarm.aadl


**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **SFT: Force variance of flow rate, check if appropriat alarm or warning is railed**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 42. Claim 2.2.B: Environmental hazards have been mitigated



### Claim 2.2.B: Environmental hazards have been mitigated

following Table B in guidance



### Strategy 2.2.B: Induction over environmental hazards



### Rationale 2.2.B: Mitigation of each environmental hazard adds confidence to safety



### Table 2 – Environmental Hazard Examples

See details in section 43



### Claim 2.2.B.1: Failure to Operate due to Environment Mitigated

See details in section 44



**Claim 2.2.B.2: Pump Exposed to Pathogens, Allergens, Hazardous Substances Mitigated**

*See details in section 45*



**Claim 2.2.B.3: Tampering mitigated**


*See details in section 46*



**Claim 2.2.B.4: Non-human Interference mitigated**

*See details in section 51*

### 43. Table 2 – Environmental Hazard Examples



 **Table 2 – Environmental Hazard Examples**


 **Table 2 – Environmental Hazard Examples**

**Evidence:** IPGenera Guidance.pdf#page=14

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## 44. Claim 2.2.B.1: Failure to Operate due to Environment Mitigated



### Claim 2.2.B.1: Failure to Operate due to Environment Mitigated

Corresponding Risk(s) to Health

Overdose Underdose Delay of therapy Electric shock

Potential Cause(s)

Temperature /Humidity/ Air pressure too high or too low



## Strategy 2.2.B.1: Restrict operation to safe environments



### Rationale 2.2.B.1: Restricting to environments for which the device was designed mitigates environmental effects



#### Restricted temperature range



##### Requirement R2.4.0(1) Temperature Range

**Evidence:** ICE-PCArequirements.pdf#nameddest=temperature range

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



##### Labeling

**Evidence:** ICE-PCArequirements.pdf#nameddest=labeling

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



#### Restricted Atmospheric Pressure



##### Requirement R2.4.0(2) Atmospheric Pressure

**Evidence:** ICE-PCArequirements.pdf#nameddest=atmospheric pressure

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



##### Labeling

**Evidence:** ICE-PCArequirements.pdf#nameddest=labeling

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



#### Restricted Relative Humidity



##### Requirement R2.4.0(3) Relative Humidity

**Evidence:** ICE-PCArequirements.pdf#nameddest=relative humidity

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



##### Labeling

**Evidence:** ICE-PCArequirements.pdf#nameddest=labeling

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## Splashing Resistance



### Requirement R2.4.0(4) Splashing

**Evidence:** ICE-PCArequirements.pdf#nameddest=splashing

**Repository:** NOR-STA SVN PCAPAC - NOR-STA




### Labeling

**Evidence:** ICE-PCArequirements.pdf#nameddest=labeling

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

# 45. Claim 2.2.B.2: Pump Exposed to Pathogens, Allergens, Hazardous Substances Mitigated



## Claim 2.2.B.2: Pump Exposed to Pathogens, Allergens, Hazardous Substances Mitigated

Corresponding Risk(s) to Health

Trauma, Infection,  
Allergic response

Potential Cause(s)

Contamination due to spillage / exposure to toxins

Battery leak

Potential Cause(s)

Contamination due to spillage / exposure to toxins



**Strategy 2.2.B.2: Don't expose to hazardous substances, limit battery leakage**



**Rationale 2.2.B.2: Prevent exposure and limiting battery leakage mitigates hazardous substances**



**Battery failure won't harm patient**



**Requirement R6.3.0(8) Component Failure**

**Evidence:** ICE-PCArequirements.pdf#nameddest=component failure

**Repository:** NOR-STA SVN PCAPAC - NOR-STA




**Hospital procedures prevent contamination**



**Wet safety**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 46. Claim 2.2.B.3: Tampering mitigated



### Claim 2.2.B.3: Tampering mitigated

(for example, by a patient during home use to adjust drug delivery)





**Strategy 2.2.B.3: Show tampering mitigated by pump features**



**Rationale 2.2.B.3: Must mitigate each different kind of tampering**



**Claim 2.2.B.3.1: Unauthorized tampering of pump settings mitigated**

*See details in section 47*



**Claim 2.2.B.3.2: Panel lock broken mitigated by having strong lock and case**

*See details in section 48*



**Claim 2.2.B.3.3: Panel/door opened during infusion mitigated by strong lock and case**


*See details in section 49*



**Claim 2.2.B.3.4: Infusion cannot be started with open door**

*See details in section 50*

## 47. Claim 2.2.B.3.1: Unauthorized tampering of pump settings mitigated



### Claim 2.2.B.3.1: Unauthorized tampering of pump settings mitigated

Pump settings defined on hard-to-fake label of drug container,  
Authentication of Rx on label  
Authentication of Clinician



### Strategy 2.2.B.3.1: Pump setting can only be read from authenticated prescription on drug container label



### Rationale 2.2.B.3.1: Can't tamper what can't be changed



### Prescriptions are read from drug container and authenticated



### **Requirement R7.1.0(3): Prescription Authentication**

**Evidence:** ICE-PCArequirements.pdf#nameddest=prescription authentication

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Architecture: PCA\_Security::Security**

**Evidence:** PCA\_Security.aadl


**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Only authenticated prescription scanned from the drug container can be used**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 48. Claim 2.2.B.3.2: Panel lock broken mitigated by having strong lock and case



### Claim 2.2.B.3.2: Panel lock broken mitigated by having strong lock and case

Lock must be hard to pick too



### Strategy 2.2.B.3.2: Argue strong lock and case mitigates breakage



### Rationale 2.2.B.3.2: Strong lock and case is hard to break



### PCA pump has strong lock and case



### Requirement R6.5.0(1) Tamper-Resistant Door

**Evidence:** ICE-PCArequirements.pdf#nameddest=tamper-resistant door

**Repository:** NOR-STA SVN PCAPAC - NOR-STA




## **Requirement R6.5.0(4) Pump Case**

**Evidence:** ICE-PCArequirements.pdf#nameddest=pump case

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 49. Claim 2.2.B.3.3: Panel/door opened during infusion mitigated by strong lock and case



**Claim 2.2.B.3.3: Panel/door opened during infusion mitigated by strong lock and case**



**Strategy 2.2.B.3.3: Argue strong lock and case mitigates door opening**



**Rationale 2.2.B.3.3: Strong lock and case makes door hard to open inappropriately**



**PCA pump has strong lock and case**



**Requirement R6.5.0(1) Tamper-Resistant Door**

**Evidence:** ICE-PCArequirements.pdf#nameddest=tamper-resistant door

**Repository:** NOR-STA SVN PCAPAC - NOR-STA




## **Requirement R6.5.0(4) Pump Case**

**Evidence:** ICE-PCArequirements.pdf#nameddest=pump case

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 50. Claim 2.2.B.3.4: Infusion cannot be started with open door



### Claim 2.2.B.3.4: Infusion cannot be started with open door

Trace to use case and architecture



### Strategy 2.2.B.3.4: Argue that requiring the door to be closed makes tampering difficult



### Rationale 2.2.B.3.4: Temperis is difficult when the door is closed



### Infusion can be started only when door is closed




### Requirement R6.5.0(2) Door Closed and Locked

**Evidence:** ICE-PCArequirements.pdf#nameddest=door closed and locked

**Repository:** NOR-STA SVN PCAPAC - NOR-STA




 **Opening the door when infusing raises alarm**

 **Requirement R6.2.0(8) Open Door Alarm**

**Evidence:** ICE-PCArequirements.pdf#nameddest=open door alarm

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 51. Claim 2.2.B.4: Non-human Interference mitigated



**Claim 2.2.B.4: Non-human Interference mitigated**



**Strategy 2.2.B.4: Mandate electromagnetic compatibility and non-interference**



**Rationale 2.2.B.4: Electromagnetic compatibility mitigates interference**



**Claim 2.2.B.4.1: Electromagnetic Interference Mitigated by Shielding of Case**

*See details in section 52*



**Claim 2.2.B.4.2: Electrostatic discharge mitigated by touch-screen and case design**


*See details in section 53*



**Claim 2.2.B.4.3: Interference from power mitigated by ferrite filter**

*See details in section 54*

## 52. Claim 2.2.B.4.1: Electromagnetic Interference Mitigated by Shielding of Case



### Claim 2.2.B.4.1: Electromagnetic Interference Mitigated by Shielding of Case

This should be added to the requirements



### Strategy 2.2.B.4.1: Argue shielding mitigates electrical interference



### Rationale 2.2.B.4.1: Shielding mitigates electrical interference



### Compliant with standard IEC 60601-1-2 (2001)

Medical Electrical Equipment, Part 1: General Requirements for Safety, 2. Collateral Standard: Electromagnetic Compatibility - Requirements and Tests




### Requirement R6.3.0(9) Electromagnetically Compatible

**Evidence:** ICE-PCArequirements.pdf#nameddest=electromagnetically compatible

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

### 53. Claim 2.2.B.4.2: Electrostatic discharge mitigated by touch-screen and case design



 **Claim 2.2.B.4.2: Electrostatic discharge mitigated by touch-screen and case design**

 **Strategy 2.2.B.4.2: Argue reducing effects of electrostatic discharge mitigate interference**

 **Rationale 2.2.B.4.2: Reducing effects of electrostatic discharge mitigate interference**

 **Effect of electrostatic discharge limited**




## **Requirement R6.3.0(10): Electrostatic Discharge**

**Evidence:** ICE-PCArequirements.pdf#nameddest=electrostatic discharge

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 54. Claim 2.2.B.4.3: Interference from power mitigated by ferrite filter



**Claim 2.2.B.4.3: Interference from power mitigated by ferrite filter**



**Strategy 2.2.B.4.3: Argue reducing interference from power mitigates interference**



**Rationale 2.2.B.4.3: Reducing interference from power mitigates interference**



**Pwer interference limited by ferrite filter**




**Requirement R6.3.0(11): Filter Power Interference**

**Evidence:** ICE-PCArequirements.pdf#nameddest=filter power interference

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 55. Claim 2.2.C: Electrical hazards have been mitigated



### Claim 2.2.C: Electrical hazards have been mitigated

following Table c in guidance

### Strategy 2.2.C: Induction over electrical hazards

### Rationale 2.2.C: Mitigation of each hazard adds confidence to safety

### Table 3 – Electrical Hazard Examples

*See details in section 56*

### Claim 2.2.C.1: Power supply overheating mitigated by shutting down if temperature gets too high

*See details in section 57*

### Claim 2.2.C.2: Backup Battery Charge Fault Mitigated by Detection and Reporting

*See details in section 58*

### Claim 2.2.C.3: Supply voltage error mitigated by monitoring and reporting

*See details in section 59*



**Claim 2.2.C.4: Battery failure mitigated by detection and reporting**

*See details in section 60*



**Claim 2.2.C.5: Leakage current mitigated by isolating mains power**

*See details in section 61*



**Claim 2.2.C.6: Power supply circuit failure mitigated by detection and shut off**

*See details in section 62*




**Claim 2.2.C.7: EMI from pump mitigated by design**

*See details in section 63*



## 56. Table 3 – Electrical Hazard Examples




### Table 3 – Electrical Hazard Examples

### Table 3 – Electrical Hazard Examples

**Evidence:** IPGenera Guidance.pdf#page=15

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 57. Claim 2.2.C.1: Power supply overheating mitigated by shutting down if temperature gets too high




 **Claim 2.2.C.1: Power supply overheating mitigated by shutting down if temperature gets too high**

 **Strategy 2.2.C.1: No power supply overheating detection**

 **Rationale 2.2.C.1: Let it fail and switch to battery backup**

 **Switch to battery backup upon power supply failure**

 **Requirement R6.3.0(1) Battery Backup**

**Evidence:** ICE-PCArequirements.pdf#nameddest=battery backup

**Repository:** NOR-STA SVN PCAPAC - NOR-STA




**Architecture: PCA\_Power::power\_control.imp**

**Evidence:** PCA\_Power.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 58. Claim 2.2.C.2: Backup Battery Charge Fault Mitigated by Detection and Reporting




 **Claim 2.2.C.2: Backup Battery Charge Fault Mitigated by Detection and Reporting**

 **Strategy 2.2.C.2: Detect and report battery failure and low battery voltage**

 **Rationale 2.2.C.2: Detecting and reporting battery problems mitigates their effect**

 **Battery problems are detected and reported**

 **Requirement R6.3.0(4) Low-Battery Warning**

**Evidence:** ICE-PCArequirements.pdf#nameddest=low-battery warning

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Requirement R6.3.0(5) Battery Failure Alarm**

**Evidence:** ICE-PCArequirements.pdf#nameddest=battery failure alarm

**Repository:** NOR-STA SVN PCAPAC - NOR-STA




### **Architecture: PCA\_Power::power\_control.imp**

**Evidence:** PCA\_Power.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 59. Claim 2.2.C.3: Supply voltage error mitigated by monitoring and reporting



 **Claim 2.2.C.3: Supply voltage error mitigated by monitoring and reporting**

 **Strategy 2.2.C.3: Detect and report power supply voltage out-of-range**

 **Rationale 2.2.C.3: Detecting and reporting power supply voltage out-of-range mitigates their effect**

 **Battery problems are detected and reported**

 **Requirement R6.3.0(6) Voltage Out-Of-Range Warning**

**Evidence:** ICE-PCArequirements.pdf#nameddest=voltage out-of-range warning

**Repository:** NOR-STA SVN PCAPAC - NOR-STA




**Architecture: PCA\_Power::power\_control.imp**

**Evidence:** PCA\_Power.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 60. Claim 2.2.C.4: Battery failure mitigated by detection and reporting




 **Claim 2.2.C.4: Battery failure mitigated by detection and reporting**

 **Strategy 2.2.C.4: Detect and report battery failure**

 **Rationale 2.2.C.4: Detecting and reporting battery failures mitigates their effect**

 **Battery failures are detected and reported**

 **Requirement R6.3.0(5) Battery Failure Alarm**

**Evidence:** ICE-PCArequirements.pdf#nameddest=battery failure alarm

**Repository:** NOR-STA SVN PCAPAC - NOR-STA






**Architecture: PCA\_Power::power\_control.imp**

**Evidence:** PCA\_Power.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 61. Claim 2.2.C.5: Leakage current mitigated by isolating mains power




 **Claim 2.2.C.5: Leakage current mitigated by isolating mains power**

 **Strategy 2.2.C.5: Limit leakage current**

 **Rationale 2.2.C.5: Limiting leakage current mitigates its hazard**


 **Leakage current limited to 10 mA**

 **Requirement R6.3.0(7) Leakage Current**

**Evidence:** ICE-PCArequirements.pdf#nameddest=leakage current

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 62. Claim 2.2.C.6: Power supply circuit failure mitigated by detection and shut off




 **Claim 2.2.C.6: Power supply circuit failure mitigated by detection and shut off**

 **Strategy 2.2.C.6: No power supply circuit failure detection**

 **Rationale 2.2.C.6: Let it fail and switch to battery backup**

 **Switch to battery backup upon power supply failure**

 **Requirement R6.3.0(1) Battery Backup**

**Evidence:** ICE-PCArequirements.pdf#nameddest=battery backup

**Repository:** NOR-STA SVN PCAPAC - NOR-STA




**Architecture: PCA\_Power::power\_control.imp**

**Evidence:** PCA\_Power.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

### 63. Claim 2.2.C.7: EMI from pump mitiageted by design



#### **Claim 2.2.C.7: EMI from pump mitiageted by design**

and verified by EMI lab testing.

Cite FCC limits on commercial site emissions

#### **Strategy 2.2.C.7: Argue shielding mitigates electrical interference**

#### **Rationale 2.2.C.7: Shielding mitigates electrical interference**

#### **Compliant with standard IEC 60601-1-2 (2001)**


Medical Electrical Equipment, Part 1: General Requirements for Safety, 2. Collateral Standard: Electromagnetic Compatibility - Requirements and Tests

#### **Requirement R6.3.0(9) Electromagnetically Compatible**

**Evidence:** ICE-PCArequirements.pdf#nameddest=electromagnetically compatible

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 64. Claim 2.2.D: Hardware hazards have been mitigated



### **Claim 2.2.D: Hardware hazards have been mitigated**

Hardware hazards are those hazards related to the failure of a hardware component of the device.  
following Table D in guidance

### **Strategy 2.2.D: Induction over hardware hazards**

### **Rationale 2.2.D: Mitigation of each hazard adds confidence to safety**

### **Table 4 – Hardware Hazard Examples**

*See details in section 65*

### **Claim 2.2.D.1: System Failure Mitigated by Safety Architecture**

*See details in section 66*

### **Claim 2.2.D.2: Network error mitigated by switching to stand-alone mode**

*See details in section 67*



**Claim 2.2.D.3: Memory failure mitigated by error correction**

*See details in section 68*



**Claim 2.2.D.4: False alarms are not hazards**

*See details in section 69*



**Claim 2.2.D.5: Missed alarm due to sensor failure mitigated by safety architecture**


*See details in section 70*



**Claim 2.2.D.6: Incorrect dose mitigated by Rx on label, authenticated**

*See details in section 71*

# 65. Table 4 – Hardware Hazard Examples



 **Table 4 – Hardware Hazard Examples**


 **Table 4 – Hardware Hazard Examples**

**Evidence:** IPGenera Guidance.pdf#page=17

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## 66. Claim 2.2.D.1: System Failure Mitigated by Safety Architecture



### Claim 2.2.D.1: System Failure Mitigated by Safety Architecture

Underdose Delay in therapy Incorrect therapy

Malfunctioning component  
Synchronization error between pump components Watchdog failure  
Reliability specification not met

### Strategy 2.2.D.1: Argue that separate safety architecture detects and mitigates faults in operation

### Rationale 2.2.D.1: Separate safety architecture detects and mitigates faults in operation

### PCA pump safety architecture mitigates system failure



## **Requirement R6.1.0(1) Safety Architecture**

**Evidence:** ICE-PCArequirements.pdf#nameddest=safety architecture

**Repository:** NOR-STA SVN PCAPAC - NOR-STA




## **Architecture: PCA\_Safety::safety.imp**

**Evidence:** PCA\_Safety.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 67. Claim 2.2.D.2: Network error mitigated by switching to stand-alone mode



 **Claim 2.2.D.2: Network error mitigated by switching to stand-alone mode**

 **Strategy 2.2.D.2: Argue that switching from ICE to stand alone is always safe**

 **Rationale 2.2.D.2: Switching from ICE to stand alone is always safe**

 **PCA pump act as stand-alone device when its ICE network connection fails**

 **Requirement R7.5.0(6) Stand-Alone**

**Evidence:** ICE-PCArequirements.pdf#nameddest=stand-alone

**Repository:** NOR-STA SVN PCAPAC - NOR-STA




**Architecture: PCA\_Operation\_Threads::ICE\_thread.imp**

**Evidence:** PCA\_Operation\_Threads.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 68. Claim 2.2.D.3: Memory failure mitigated by error correction



**Claim 2.2.D.3: Memory failure mitigated by error correction**



**Strategy 2.2.D.3: Argue that error correction masks some memory errors**



**Rationale 2.2.D.3: Error correction masks some memory errors**



**Continuous fault detection and correction masks memory errors**



**Requirement: R6.4.0(3) Continuous Fault-Detection**

**Evidence:** ICE-PCArequirements.pdf#nameddest=continuous fault-detection

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



#### **Requirement: R6.4.0(4) Single-Event Upsets**

**Evidence:** ICE-PCArequirements.pdf#nameddest=single-event upsets

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



#### **Requirement: R6.4.0(5) Masked Faults**

**Evidence:** ICE-PCArequirements.pdf#nameddest=masked faults

**Repository:** NOR-STA SVN PCAPAC - NOR-STA




#### **Requirement: R6.4.0(6) Hardware Detected Faults**

**Evidence:** ICE-PCArequirements.pdf#nameddest=hardware detected faults

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 69. Claim 2.2.D.4: False alarms are not hazards




 **Claim 2.2.D.4: False alarms are not hazards**

 **Strategy 2.2.D.4: Argue that false alarms are not hazards**

 **Rationale 2.2.D.4: False alarms are annoying, and may cause alarm fatigue, but are not themselves hazards**

## 70. Claim 2.2.D.5: Missed alarm due to sensor failure mitigated by safety architecture




 **Claim 2.2.D.5: Missed alarm due to sensor failure mitigated by safety architecture**

 **Strategy 2.2.D.5: Argue that separate safety architecture detects and mitigates sensor failure**

 **Rationale 2.2.D.5: Separate safety architecture detects and mitigates sensor failure by continuously monitoring sensors and sounding alarm upon failure**

 **PCA pump safety architecture mitigates sensor failure by monitoring and alarm if failed**

 **Requirement R6.1.0(1) Safety Architecture**


**Evidence:** ICE-PCArequirements.pdf#nameddest=safety architecture

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Architecture: PCA\_Safety::safety.imp**

**Evidence:** PCA\_Safety.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Requirement R6.2.0(4) Upstream Occlusion Alarm**

**Evidence:** ICE-PCArequirements.pdf#nameddest=upstream occlusion alarm

**Repository:** NOR-STA SVN PCAPAC - NOR-STA





### **Requirement R6.2.0(5) Downstream Occlusion Alarm**

**Evidence:** ICE-PCArequirements.pdf#nameddest=downstream occlusion alarm

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Requirement R6.1.0(1) Safety Architecture**

**Evidence:** ICE-PCArequirements.pdf#nameddest=safety architecture

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Flow sensor failure detected and warning or alarm issued**



### **Requirement R5.4.0(2) Basal Over-Infusion Alarm**

**Evidence:** ICE-PCArequirements.pdf#nameddest=basal over-infusion alarm

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Requirement R5.4.0(3) Basal Under-Infusion Warning**

**Evidence:** ICE-PCArequirements.pdf#nameddest=basal under-infusion warning

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Requirement R5.4.0(4) Bolus Over-Infusion Alarm**

**Evidence:** ICE-PCArequirements.pdf#nameddest=bolus over-infusion alarm

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Requirement R5.4.0(5): Bolus Under-Infusion Warning**

**Evidence:** ICE-PCArequirements.pdf#nameddest=bolus under-infusion warning

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Requirement R5.4.0(6): Square Bolus Over-Infusion Alarm**

**Evidence:** ICE-PCArequirements.pdf#nameddest=square bolus over-infusion alarm

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Requirement R5.4.0(7) Square Bolus Under-Infusion Warning**

**Evidence:** ICE-PCArequirements.pdf#nameddest=square bolus under-infusion warning

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Architecture: PCA\_Alarm::Flow\_Rate\_Checker.imp**

**Evidence:** PCA\_Alarm.aadl


**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**SFT: Force variance of flow rate, check if appropriat alarm or warning is railed**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 71. Claim 2.2.D.6: Incorrect dose mitigated by Rx on label, authenticated




 **Claim 2.2.D.6: Incorrect dose mitigated by Rx on label, authenticated**

 **Strategy 2.2.D.6: Scanning and authenticating the prescription from the label on the drug container obviates many mechanical and use hazards**


 **Rationale 2.2.D.6: Scanning prescription avoids entry errors; authentication mitigates hazard the label is mis-read**

 **Prescriptions are scanned from drug label**

 **Requirement R7.1.0(3) Prescription Authentication**

**Evidence:** ICE-PCArequirements.pdf#nameddest=prescription authentication

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Requirement R5.1.0(3) Scan Drug's Package Label**

**Evidence:** ICE-PCArequirements.pdf#nameddest=drug's package label

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Architecture: PCA\_Mechanical::scanner.imp**

**Evidence:** PCA\_Mechanical.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Architecture: PCA\_Security::security.imp**

**Evidence:** PCA\_Security.aadl


**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**SFT: read prescription from label, check authentication**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 72. Claim 2.2.E: Software hazards have been mitigated



### Claim 2.2.E: Software hazards have been mitigated

following Table E in guidance

### Strategy 2.2.E: Induction over software hazards

### Rationale 2.2.E: Mitigation of each hazard adds confidence to safety

### Table 5 – Software Hazard Examples

See details in section 73

### Claim 2.2.E.1: Data errors in event and fault logs are mitigated by fault masking and sending event reports to ICE as they occur

See details in section 74

### Claim 2.2.E.2: Software runtime errors mitigated by proving program correctness and avoiding problematic software functions

See details in section 75

### Claim 2.2.E.3: Corrupted Infusion Commands mitigated by limiting their possible function

See details in section 76



**Claim 2.2.E.4: Pump could not be silenced by alarm inactivation**

*See details in section 77*



**Claim 2.2.E.5: Incorrect Software mitigated by version control**

*See details in section 78*



**Claim 2.2.E.6: Incorrect drug library loaded mitigated by authentication**


*See details in section 79*



**Claim 2.2.E.7: Failure to install software updates mitigated by manufacturer and hospital process**

*See details in section 80*

### 73. Table 5 – Software Hazard Examples




 **Table 5 – Software Hazard Examples**

 **Table 5 – Software Hazard Examples**

**Evidence:** IPGenera Guidance.pdf#page=18

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 74. Claim 2.2.E.1: Data errors in event and fault logs are mitigated by fault masking and sending event reports to ICE as they occur




 **Claim 2.2.E.1: Data errors in event and fault logs are mitigated by fault masking and sending event reports to ICE as they occur**

 **Strategy 2.2.E.1: Argue fault masking and redundant recording mitigate data errors**


 **Rationale 2.2.E.1: Memory error correction masks many data errors, sending event to ICE as they occur provides redundant backup**

 **Continuous fault detection and correction masks memory errors**

 **Requirement: R6.4.0(3) Continuous Fault-Detection**

**Evidence:** ICE-PCArequirements.pdf#nameddest=continuous fault-detection

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Requirement: R6.4.0(4) Single-Event Upsets**

**Evidence:** ICE-PCArequirements.pdf#nameddest=single-event upsets

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Requirement: R6.4.0(5) Masked Faults**

**Evidence:** ICE-PCArequirements.pdf#nameddest=masked faults

**Repository:** NOR-STA SVN PCAPAC - NOR-STA





### **Requirement: R6.4.0(6) Hardware Detected Faults**

**Evidence:** ICE-PCArequirements.pdf#nameddest=hardware detected faults

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Architecture: PCA\_Safety::error\_detector.imp**

**Evidence:** PCA\_Safety.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Architecture: PCA\_Pump::PCA\_memory.imp**

**Evidence:** PCA\_Pump.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Sending events to ICE provides another copy of data if corrupted or lost in device**



### **Requirement: R5.7.0(2) ICE Alarms**

**Evidence:** ICE-PCArequirements.pdf#nameddest=ICE alarms

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Architecture: PCA\_System::ice\_bus\_adaptor.imp**

**Evidence:** PCA\_System.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA








### **Architecture: PCA\_Operation\_Threads::ICE\_thread.imp**

**Evidence:** PCA\_Operation\_Threads.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 75. Claim 2.2.E.2: Software runtime errors mitigated by proving program correctness and avoiding problematic software functions



-  **Claim 2.2.E.2: Software runtime errors mitigated by proving program correctness and avoiding problematic software functions**
-  **Strategy 2.2.E.2: Argue avoiding problematic software function prevents problems from them and that correctness proof enhance confidence that software meets it specification**
-  **Rationale 2.2.E.2: Avoiding problematic software function prevents problems from them and that correctness proof enhance confidence that software meets it specification**
-  **No buffers are used so cannot overflow**



**Can't reference the absence of something**

Repository: NOR-STA SVN PCAPAC - NOR-STA



**No dynamic memory allocation or pointers are used, so the can't be null**



**Can't reference the absence of something**

Repository: NOR-STA SVN PCAPAC - NOR-STA



**No memory is allocated, so it can't leak**



**Can't reference the absence of something**

Repository: NOR-STA SVN PCAPAC - NOR-STA



**All variables are initialized in their declaration**



**Examine variable declarations in every thread**

Repository: NOR-STA SVN PCAPAC - NOR-STA




**No dynamic libraries are used so cannot be incorrect**



**Can't reference the absence of something**


Repository: NOR-STA SVN PCAPAC - NOR-STA

## 76. Claim 2.2.E.3: Corrupted Infusion Commands mitigated by limiting their possible function



 **Claim 2.2.E.3: Corrupted Infusion Commands mitigated by limiting their possible function**

 **Strategy 2.2.E.3: Argue limiting ICE commands to safe operations precludes their corruption**


 **Rationale 2.2.E.3: ICE can only suspend and resume infusion or inactivate alarms which cannot cause harm**

 **ICE commands limited to suspend and resume infusion and alarm inactivation**

 **Requirement: R5.7.0(4) ICE KVO Rate**


**Evidence:** ICE-PCArequirements.pdf#nameddest=cICE KVO rate

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Requirement: R5.7.0(5) ICE Resume Infusion**

**Evidence:** ICE-PCArequirements.pdf#nameddest=ICE resume infusion


**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Requirement: R5.7.0(7) ICE Inactivate Alarms**

**Evidence:** ICE-PCArequirements.pdf#nameddest=ICE inactivate alarms

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 77. Claim 2.2.E.4: Pump could not be silenced by alarm inactivation



**Claim 2.2.E.4: Pump could not be silenced by alarm inactivation**




**Strategy 2.2.E.4: Unplug pump from power, and defenestrate it**



**Rationale 2.2.E.4: Throwing the alarming device out the window may not silence alarms, but you won't hear it so loudly any more**

## 78. Claim 2.2.E.5: Incorrect Software mitigated by version control



**Claim 2.2.E.5: Incorrect Software mitigated by version control**



**Strategy 2.2.E.5: Proper version control prevents incorrect software versions or updates to be fielded**




**Rationale 2.2.E.5: FDA Quality System Regulation requires proper version control**



**Version control is a business process issue (wet safety) that cannot be mitigated by device design**

## 79. Claim 2.2.E.6: Incorrect drug library loaded mitigated by authentication




 **Claim 2.2.E.6: Incorrect drug library loaded mitigated by authentication**

 **Strategy 2.2.E.6: Argue that drug library authentication mitigates mistakes and deliberate forgery**

 **Rationale 2.2.E.6: Drug library authentication makes it difficult to install an incorrect drug library**

 **Drug libraries are authenticated**

 **Requirement: R7.1.0(4) Drug Library Authentication**

**Evidence:** ICE-PCArequirements.pdf#nameddest=drug library authentication

**Repository:** NOR-STA SVN PCAPAC - NOR-STA






**Architecture: PCA\_Security::security.imp**

**Evidence:** PCA\_Security.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 80. Claim 2.2.E.7: Failure to install software updates mitigated by manufacturer and hospital process



**Claim 2.2.E.7: Failure to install software updates mitigated by manufacturer and hospital process**



**Strategy 2.2.E.7: Proper version control prevents incorrect software versions or updates to be fielded**




**Rationale 2.2.E.7: FDA Quality System Regulation requires proper version control**



**Version control is a business process issue (wet safety) that cannot be mitigated by device design**

## 81. Claim 2.2.F: Mechanical hazards have been mitigated



### Claim 2.2.F: Mechanical hazards have been mitigated

following Table F in guidance

### Strategy 2.2.F: Induction over mechanical hazards

### Rationale 2.2.F: Mitigation of each hazard adds confidence to safety

### Table 6 – Mechanical Hazard Examples

*See details in section 82*

### Claim 2.2.F.1: Unable to set dose mitigated by scanning Rx from label

*See details in section 83*

### Claim 2.2.F.2: Failure to alarm by broken speaker mitigated by alarm through ICE and audible test

*See details in section 84*



**Claim 2.2.F.3: Broken power cord mitigated by eletrocuting users**


*See details in section 85*



**Claim 2.2.F.4: Pump motor failure mitigated by alarm upon pump stopping**

*See details in section 86*

# 82. Table 6 – Mechanical Hazard Examples




 **Table 6 – Mechanical Hazard Examples**

 **Table 6 – Mechanical Hazard Examples**

**Evidence:** IPGenera Guidance.pdf#page=12

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 83. Claim 2.2.F.1: Unable to set dose mitigated by scanning Rx from label




 **Claim 2.2.F.1: Unable to set dose mitigated by scanning Rx from label**

 **Strategy 2.2.F.1: Scanning and authenticating the prescription from the label on the drug container obviates many mechanical and use hazards**


 **Rationale 2.2.F.1: Scanning prescription avoids entry errors; authentication mitigates hazard the label is mis-read**

 **Prescriptions are scanned from drug label**

 **Requirement R7.1.0(3) Prescription Authentication**

**Evidence:** ICE-PCArequirements.pdf#nameddest=prescription authentication

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Requirement R5.1.0(3) Scan Drug's Package Label**

**Evidence:** ICE-PCArequirements.pdf#nameddest=drug's package label

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Architecture: PCA\_Mechanical::scanner.imp**

**Evidence:** PCA\_Mechanical.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Architecture: PCA\_Security::security.imp**

**Evidence:** PCA\_Security.aadl


**Repository:** NOR-STA SVN PCAPAC - NOR-STA






**SFT: read prescription from label, check authentication**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

**84. Claim 2.2.F.2: Failure to alarm by broken speaker mitigated by alarm through ICE and audible test**



-  **Claim 2.2.F.2: Failure to alarm by broken speaker mitigated by alarm through ICE and audible test**
-  **Argue that audible test ensures speaker works when beginning infusion, and that alarms through ICE mitigate sound failure during operation**
-  **Audible test ensure initially working speaker; ICE alarm mitigates failure during operation**





### **Audible test ensures working speaker when starting infusion**



### **Requirement R5.5.0(19) Confirm Sound of Audible Alarm**

**Evidence:** ICE-PCArequirements.pdf#nameddest=sound of audible alarm

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Redundant alarm when connected to ICE**




### **Requirement R5.7.0(2): ICE alarms**

**Evidence:** ICE-PCArequirements.pdf#nameddest=ICE alarms

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 85. Claim 2.2.F.3: Broken power cord mitigated by eletrocuting users




 **Claim 2.2.F.3: Broken power cord mitigated by eletrocuting users**

 **Argue dead users won't use PCA Pump with broken power cord again**

Yes, this is a joke.

 **Deaim men infuse no drug**

## 86. Claim 2.2.F.4: Pump motor failure mitigated by alarm upon pump stopping



 **Claim 2.2.F.4: Pump motor failure mitigated by alarm upon pump stopping**

 **Strategy 2.2.F.5 Argue that alarm mitigates failure**

 **Rationale 2.2.F.5 When notified of pump failure by alarm, clinician can substitute working pump**

 **Under-infusion warning when pump stops**

 **Requirement R5.4.0(3) Basal Under-Infusion Warning**

**Evidence:** ICE-PCArequirements.pdf#nameddest=basal under-infusion warning

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Requirement R5.4.0(5): Bolus Under-Infusion Warning**

**Evidence:** ICE-PCArequirements.pdf#nameddest=bolus under-infusion warning

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Requirement R5.4.0(7) Square Bolus Under-Infusion Warning**

**Evidence:** ICE-PCArequirements.pdf#nameddest=square bolus under-infusion warning

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Architecture: PCA\_Alarm::Flow\_Rate\_Checker.imp**

**Evidence:** PCA\_Alarm.aadl


**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **SFT: artificially force pump stoppage, check for warning(s)**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 87. Claim 2.2.G: Biological and chemical hazards have been mitigated



### Claim 2.2.G: Biological and chemical hazards have been mitigated

following Table G in guidance



### Strategy 2.2.G: Biological and chemical hazards are mitigated by using biocompatible materials, and proper procedure



### Rationale 2.2.G: These are mostly 'wet' safety hazards, or material issues unrelated to system design

Wet safety hazards arise from human misuse of the product, few of which can be mitigated by dry safety features. Therefore, mitigation of many misuse hazards can only be procedural, addressed by clinician training and restriction to authenticated users.

The exception is reminding to flush, and adapt priming functionality to do something similar with cleaning fluid after use.



### Table 7 – Biological and Chemical Hazard Examples








See details in section 88




### Claim 2.2.G.1: Hazard of inadequate device cleaning mitigated by user training and certification



### Claim 2.2.G.2: Hazard of contamination by blood or leaking fluid mitigated by proper cleaning

-  **Claim 2.2.G.3: Hazard of failure to flush mitigated by control panel message reminder**
-  **Claim 2.2.G.4: Hazard of pump connected to non-sterile infusion sets mitigated by training and certification**
-  **Claim 2.2.G.5: Hazard of packaging of the pump is damaged prior to its use mitigated by receiving inspection**
-  **Claim 2.2.G.6: Hazard of patient allergy to the infusion set or infusion set adhesive by knowing allergies of patient and comparing with material of infusion set**
-  **Claim 2.2.G.7: Hazard of clinician fails to rotate infusion sites as recommended mitigated by training and certification**
-  **Claim 2.2.G.8: Hazard of chemical precipitation inside the delivery path mitigated by cleaning and material compatibility**
-  **Claim 2.2.G.9: Hazard of physical damage to pump from Inadequate device cleaning or disinfection mitigated by user training**

# 88. Table 7 – Biological and Chemical Hazard Examples




 **Table 7 – Biological and Chemical Hazard Examples**

 **Table 7 – Biological and Chemical Hazard Examples**

**Evidence:** IPGenera Guidance.pdf#page=20

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 89. Claim 2.2.H: Use hazards have been mitigated



### Claim 2.2.H: Use hazards have been mitigated

following Table H in FDA guidance

### Strategy 2.2.H: Induction over use hazards

### Rationale 2.2.H: Mitigation of each hazard adds confidence to safety

### Table 8 – Use Hazard Examples

See details in section 90

### Claim 2.2.H.1: The hazard of user not understanding how to initiate pump operation is mitigated by clinician authentication and training

See details in section 91

### Claim 2.2.H.2: Incorrect prescription mitigated by prescription authentication

See details in section 92

### Claim 2.2.H.3: The hazard that infusion is stopped prematurely can only be mitigated by proper procedure

See details in section 93

### Claim 2.2.H.4: The hazard that the user fails to detect notifications is mitigated

See details in section 94





**Claim 2.2.H.5: The wrong drug hazard has been mitigated by authenticating Rx.**

*See details in section 97*



**Claim 2.2.H.6: Physical set up is correct**

*See details in section 98*



**Claim 2.2.H.7: Users cannot "work around" or "bypass" software limits on drug/dose parameters**

*See details in section 99*



**Claim 2.2.H.8: The hazard that clinicians ignore warnings and alarms is mitigated**

*See details in section 100*



**Claim 2.2.H.9: Clinicians do not misinterpret alarms/warnings**

*See details in section 102*



**Claim 2.2.H.10: Users understand pump status and operational modes**

*See details in section 105*



**Claim 2.2.H.11: The user's motion cause motion causes the pump to be disconnected from the user.**

This is a 'wet' safety hazard that pump design can do nothing about



**Claim 2.2.H.12: The self over-medication hazard has been mitigated by requiring a minimum time between patient boluses.**

*See details in section 106*



**Claim 2.2.H.13: The clinician follows instructions to disconnect the pump**

*See details in section 107*



**Claim 2.2.H.14: The hazard of giving the drug to the wrong patient has been mitigated by patient authentication.**


*See details in section 108*



**Claim 2.2.H.15: The use by unauthorized persons hazard has been mitigated by clinician authentication.**

*See details in section 109*

# 90. Table 8 – Use Hazard Examples




 **Table 8 – Use Hazard Examples**

 **Table 8 – UsewHazard Examples**

**Evidence:** IPGenera Guidance.pdf#page=22

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 91. Claim 2.2.H.1: The hazard of user not understanding how to initiate pump operation is mitigated by clinician authentication and training




 **Claim 2.2.H.1: The hazard of user not understanding how to initiate pump operation is mitigated by clinician authentication and training**

 **Mitigation 2.2.H.1: Clinician authentication and clinician training**

 **Rationale 2.2.H.1: Authentication prevents use by untrained persons**

 **Clinicians are authenticated before use allowed**

 **Requirement R7.1.0(1): Clinician Authentication**

**Evidence:** ICE-PCArequirements.pdf#nameddest=clinician authentication

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Architecture: PCA\_Security::Security**

**Evidence:** PCA\_Security.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**System Feture Test: Pump can only be operated by authenticated clinician**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Clinicians are properly trained**




**Labeling: Clinicians using the device must be trained; only trained clinicians may be authenticated.**

**Evidence:** ICE-PCArequirements.pdf#nameddest=labeling

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 92. Claim 2.2.H.2: Incorrect prescription mitigated by prescription authentication




 **Claim 2.2.H.2: Incorrect prescription mitigated by prescription authentication**

 **Strategy 2.2.H.2: Having prescription electronically read from drug container, and authenticated ensures the prescription from the pharmacy is used during operation**

 **Rationale 2.2.H.2: Reading Rx from drug container precludes mistakes in entry, and authentication precludes deliberate mis-entry**

 **Prescriptions are read from drug container and authenticated**

 **Requirement R7.1.0(3): Prescription Authentication**

**Evidence:** ICE-PCArequirements.pdf#nameddest=prescription authentication

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **Architecture: PCA\_Security::Security**

**Evidence:** PCA\_Security.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **SFT 2.2.H.2: Only authenticated prescription scanned from the drug container can be used**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **Physician prescribes correctly**



## **Physician education, experience, and judgement**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **Pharmacy fills prescription correctly, and attaches correct label**



## **Pharmacist education, training, and judgement**


**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **Hospital procedures for prescribing, transmitting and filling prescriptions**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

**93. Claim 2.2.H.3: The hazard that infusion is stopped prematurely can only be mitigated by proper procedure**



 **Claim 2.2.H.3: The hazard that infusion is stopped prematurely can only be mitigated by proper procedure**

 **Strategy 2.2.H.3: Anyone can press the Stop Button to halt infusion**

 **Rationale 2.2.H.3: Necessity to allow halting of infusion when (possibly) unsafe make the risk that infusion is stopped prematurely unpreventable**

 **Stop button halts infusion**

 **Requirement R5.5.0(6): Stop Button**

**Evidence:** ICE-PCArequirements.pdf#nameddest=stop button

**Repository:** NOR-STA SVN PCAPAC - NOR-STA





### **Requirement R5.5.0(7): Stop Infusion**

**Evidence:** ICE-PCArequirements.pdf#nameddest=stop infusion

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **PCA\_Control\_Panel::ui\_thread**

**Evidence:** PCA\_Control\_Panel.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Start button resumes infusion**



### **Requirement R5.5.0(2): Start Button**

**Evidence:** ICE-PCArequirements.pdf#nameddest=start button

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Requirement R5.5.0(22): Resume Infusion**

**Evidence:** ICE-PCArequirements.pdf#nameddest=resume infusion

**Repository:** NOR-STA SVN PCAPAC - NOR-STA




### **PCA\_Control\_Panel::ui\_thread**

**Evidence:** PCA\_Control\_Panel.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 94. Claim 2.2.H.4: The hazard that the user fails to detect notifications is mitigated



 **Claim 2.2.H.4: The hazard that the user fails to detect notifications is mitigated**


 **Strategy 2.2.H.4: Pump makes audible alarms, which are heard by clinician(s), and not ignored**

 **Rationale 2.2.H.4: To detect audible notification they must be heard and not ignored**

 **Claim 2.2.H.4.1: Alarm fatigue is avoided by only raising necessary alarms**

*See details in section 95*

 **Audio test ensures pump can sound alarms**

 **Requirement R.5.5.0(19) Sound of Audible Alarm Test**

**Evidence:** ICE-PCArequirements.pdf#nameddest=sound of audible alarm

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Architecture: PCA\_Control\_Panel::pca\_speaker**

**Evidence:** PCA\_Control\_Panel.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Architecture: PCA\_Boss::Boss\_Thread.imp => UC1\_2\_make\_sound EC17\_audio\_fail**

**Evidence:** PCA\_Boss.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## **Issues alarms and warnings**

### **Requirement R5.4.0(1) Issue Alarms and Warnings**

**Evidence:** ICE-PCArequirements.pdf#nameddest=issue alarms and warnings

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## **Audibly sounds alarms**

### **Requirement R5.5.0(12) Sound Alarm**

**Evidence:** ICE-PCArequirements.pdf#nameddest=sound alarm

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

### **Architecture: PCA\_Control\_Panel::pca\_speaker**

**Evidence:** PCA\_Control\_Panel.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## **Alarms can be inactivated**

Because alarms can be inactivated, they may not be heard.

### **Requirements: R4.4.0(14) Inactivate Audible Alarms Indefinitely**

**Evidence:** ICE-PCArequirements.pdf#nameddest=inactivate audible alarms indefinitely

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

### **Requirements: R4.4.0(15) Inactivate Audible Alarms Temporarily**

**Evidence:** ICE-PCArequirements.pdf#nameddest=inactivate audible alarms temporarily

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## **Claim 2.2.H.4.2: Background noise will not cause user(s) to fail to detect notification(s)**

*See details in section 96*

## **Alarms will be loud enough**



### **Requirement R5.4.3(2) Auditory Volume**

**Evidence:** ICE-PCArequirements.pdf#nameddest=auditory volume

**Repository:** NOR-STA SVN PCAPAC - NOR-STA




### **Architecture: PCA\_Control\_Panel::pca\_speaker**

**Evidence:** PCA\_Control\_Panel.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 95. Claim 2.2.H.4.1: Alarm fatigue is avoided by only raising necessary alarms




 **Claim 2.2.H.4.1: Alarm fatigue is avoided by only raising necessary alarms**

 **Strategy 2.2.H.1: This is an unverifiable claim**


 **Definition of necessary alarm is inherently subjective, and alarm fatigue can only be judged by those who hear the alarms**

**96. Claim 2.2.H.4.2: Background noise will not cause user(s) to fail to detect notification(s)**




 **Claim 2.2.H.4.2: Background noise will not cause user(s) to fail to detect notification(s)**

 **Strategy 2.2.H.4.2: Background noise is a function of place of use**

 **Rationale 2.2.H.4.2: This claim is unverifiable**

## 97. Claim 2.2.H.5: The wrong drug hazard has been mitigated by authenticating Rx.



 **Claim 2.2.H.5: The wrong drug hazard has been mitigated by authenticating Rx.**

 **Trace mitigation to requirements, architecture, SFT**

 **Tracing is how the fact of mitigation is established**

 **Trace Mitigation to Architecture**

 **PCA\_Security::security**

**Evidence:** PCA\_Security.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## Trace Mitigation to Test



## Prescription Authentication Test

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## Trace Mitigation to Requirements




## Requirement 7.1.0(3) Prescription Authentication

**Evidence:** ICE-PCArequirements.pdf#nameddest=prescription authentication

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## 98. Claim 2.2.H.6: Physical set up is correct



 **Claim 2.2.H.6: Physical set up is correct**

 **Mitigation 2.2.H.6: Physical set up, such as routing of tubing or selection of appropriate tubing set cannot be assured**

 **Rationale 2.2.H.6: Clinicians administering PCA must do it right; nothing in pump design can help**

 **Clinicians are authenticated before use allowed**

 **Clinician Authentication**

**Evidence:** ICE-PCArequirements.pdf#nameddest=clinician authentication

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **PCA\_Security::Security**

**Evidence:** PCA\_Security.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **Pump can only be operated by authenticated clinician**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **Clinicians are properly trained**




## **Clinicians using the device must be trained; only trained clinicians may be authenticated.**

**Evidence:** ICE-PCArequirements.pdf#nameddest=labeling

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 99. Claim 2.2.H.7: Users cannot "work around" or "bypass" software limits on drug/dose parameters




 **Claim 2.2.H.7: Users cannot "work around" or "bypass" software limits on drug/dose parameters**

 **Strategy 2.2.H.7: Authenticated prescription and drug library hard/soft limits preclude work arounds**

 **Rationale 2.2.H.7: PCA Pump features prevent anything other than correct prescription use**

 **Prescriptions are authenticated**

 **Requirement R7.1.0(3): Prescription Authentication**

**Evidence:** ICE-PCArequirements.pdf#nameddest=prescription authentication

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Architecture: PCA\_Security::Security**

**Evidence:** PCA\_Security.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**SFT: Only authenticated prescription scanned from the drug container can be used**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Drug library enforces hard/soft limits**



**Requirement R5.9.0(3): Drug Library Checking**

**Evidence:** ICE-PCArequirements.pdf#nameddest=drug library checking

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Architecture: PCA\_Drug\_Library::drug\_library\_thread.imp**

**Evidence:** PCA\_Drug\_Library.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Architecture: PCA\_Operation\_Threads::Prescription\_Checker.imp**

**Evidence:** PCA\_Operation\_Threads.aadl


**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**SFT: Drug library is accessed for drug prescribed and hard/soft limits checked**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

# 100. Claim 2.2.H.8: The hazard that clinicians ignore warnings and alarms is mitigated




 **Claim 2.2.H.8: The hazard that clinicians ignore warnings and alarms is mitigated**

 **Strategy 2.2.H.8: Make alarms/warnings loud, distinctive, and redundant**


 **Rationale 2.2.H.8: Loud, distinctive alarms/warnings are hard to ignore, minimizing false alarms reduces alarm fatigue, redundant alarms make it more likely that someone will hear/see them**

 **Fact 2.2.H.8.1: Alarm/warning tone and volume follow IEC 60601-1-8 1.3.1**

 **Requirement R5.4.3(1) Audible Alarm Signals**

**Evidence:** ICE-PCArequirements.pdf#nameddest=audible alarms signals

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Requirement R5.4.3(2) Auditory Volume**

**Evidence:** ICE-PCArequirements.pdf#nameddest=auditory volume

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Requirement R5.4.3(1) Alarm Melody**

**Evidence:** ICE-PCArequirements.pdf#nameddest=alarm melody

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Architecture: PCA\_Control\_Panel::pca\_speaker.imp and PCA\_Control\_Panel.ui\_thread.imp**

**Evidence:** PCA\_Control\_Panel.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**SFT: Measure alarm/warning volume and tone**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Claim 2.2.H.8.1: False alarms/warnings are minimized to reduce alarm fatigue**

*See details in section 101*



**Fact 2.2.H.8.2: Alarms/warnings sounded and displayed on control panel and ICE console**



**Requirement R5.7.0(2): ICE Alarms**

**Evidence:** ICE-PCArequirements.pdf#nameddest=ICE alarms

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Architecture: PCA\_Operation\_Threads::ICE\_Thread.imp**

**Evidence:** PCA\_Operation\_Threads.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Architecture: PCA\_System::ice\_bus\_adaptor.imp**

**Evidence:** PCA\_System.aadl


**Repository:** NOR-STA SVN PCAPAC - NOR-STA




**SFT: Alarms/warning relayed to ICE console**


**Repository:** NOR-STA SVN PCAPAC - NOR-STA

# 101. Claim 2.2.H.8.1: False alarms/warnings are minimized to reduce alarm fatigue




 **Claim 2.2.H.8.1: False alarms/warnings are minimized to reduce alarm fatigue**

 **Strategy 2.2.H.8.1: No way to verify that alarms/warnings are minimized, or that alarm fatigue is reduced.**

 **Rationale 2.2.H.8.1: This is 'wet' safety**

## 102. Claim 2.2.H.9: Clinicians do not misinterpret alarms/warnings



### Claim 2.2.H.9: Clinicians do not misinterpret alarms/warnings

### Strategy 2.2.H.9: Use standard symbols and sounds; meaningful, unambiguous messages

### Rationale 2.2.H.9: Standard symbols are commonly understood; meaningful, unambiguous messages are understood

### Claim 2.2.H.9.1: Standard symbols and sounds reduce misinterpretation

See details in section 103

### Fact 2.2.H.9.1: Alarm/warning tone and volume follow IEC 60601-1-8 1.3.1

### Requirement R5.4.3(1) Audible Alarm Signals

**Evidence:** ICE-PCArequirements.pdf#nameddest=audible alarms signals

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

### Requirement R5.4.3(2) Auditory Volume

**Evidence:** ICE-PCArequirements.pdf#nameddest=auditory volume

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

### Requirement R5.4.3(1) Alarm Melody

**Evidence:** ICE-PCArequirements.pdf#nameddest=alarm melody

**Repository:** NOR-STA SVN PCAPAC - NOR-STA





### **Architecture: PCA\_Control\_Panel::pca\_speaker.imp and PCA\_Control\_Panel.ui\_thread.imp**

**Evidence:** PCA\_Control\_Panel.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **SFT: Measure alarm/warning volume and tone**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Claim 2.2.H.9.2: Messages are meaningful and unambiguous**

*See details in section 104*



### **Fact 2.2.H.9.2: Control panel displays helpful messages**



### **Requirement R5.5.0(4) Helpful messages**

**Evidence:** ICE-PCArequirements.pdf#nameddest=helpful messages

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **Architecture: PCA\_Control\_Panel.ui\_thread.imp**

**Evidence:** PCA\_Control\_Panel.aadl


**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### **SFT: Verfiy helpful messages**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

### 103. Claim 2.2.H.9.1: Standard symbols and sounds reduce misinterpretation




 **Claim 2.2.H.9.1: Standard symbols and sounds reduce misinterpretation**

 **Strategy 2.2.H.9.1: Make unsupported claim**

 **Rationale 2.2.H.9.1: Presume that standard sounds and symbols are commonly, and unambiguously understood**

## 104. Claim 2.2.H.9.2: Messages are meaningful and unambiguous



**Claim 2.2.H.9.2: Messages are meaningful and unambiguous**



**Strategy 2.2.H.9.2: Test focus group of clinicians for their understanding of messages**



**Rationale 2.2.H.9.2: Asking users is the only way to assess understanding**




**Fact 2.2.H.9.2.1: Clinician focus groups understand messages**



**Focus group summary**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 105. Claim 2.2.H.10: Users understand pump status and operational modes



 **Claim 2.2.H.10: Users understand pump status and operational modes**

 **Strategy 2.2.H.10: Test focus group of clinicians for their understanding of status and modes**


 **Rationale 2.2.H.10: Asking users is the only way to assess understanding**

 **Fact 2.2.H.10.1: Clinician focus groups understand status and modes**

 **Focus group summary**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Fact 2.2.H.10.2: Infusion rate displayed on control panel and ICE console**

 **Requirement R5.5.0(23): Display Infusion Rate**

**Evidence:** ICE-PCArequirements.pdf#nameddest=display infusion rate

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Architecture: PCA\_Control\_Panel::ui\_thread.imp**

**Evidence:** PCA\_Control\_Panel.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Requirement R5.7.0(1): ICE Operating Status**

**Evidence:** CE-PCArequirements.pdf#nameddest=ICE operating status

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



**Architecture: PCA\_Operation\_Threads::ICE\_Thread.imp**

**Evidence:** PCA\_Operation\_Threads.aadl


**Repository:** NOR-STA SVN PCAPAC - NOR-STA




**SFT: Check that infusion rate/operating status displayed on control panel and ICE console**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

**106. Claim 2.2.H.12: The self over-medication hazard has been mitigated by requiring a minimum time between patient boluses.**



 **Claim 2.2.H.12: The self over-medication hazard has been mitigated by requiring a minimum time between patient boluses.**

 **Trace mitigation to requirements, architecture, SFT**

 **Tracing is how the fact of mitigation is established**

 **Trace Mitigation to Requirements**

 **Requirement R4.2.0(3): Minimum Time Between Patient-Requested Bolus**

**Evidence:** ICE-PCArequirements.pdf#nameddest=minimum time between patient-requested bolus

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Trace Mitigation to Architecture**

 **Architecture: PCA\_Operation\_Threads::Patient\_Bolus\_Checker.imp**

**Evidence:** PCA\_Operation\_Threads.aadl


**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Trace Mitigation to Test**

 **SFT: Show that no patient bolus delivered before minimum time between bolus**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 107. Claim 2.2.H.13: The clinician follows instructions to disconnect the pump




 **Claim 2.2.H.13: The clinician follows instructions to disconnect the pump**


 **Strategy 2.2.H.13: Clinician training to disconnect pump**

 **Rationale 2.2.H.13: Wet safety that cannot be accomplished by pump (Use Case 1 step 17)**



**108. Claim 2.2.H.14: The hazard of giving the drug to the wrong patient has been mitigated by patient authentication.**




 **Claim 2.2.H.14: The hazard of giving the drug to the wrong patient has been mitigated by patient authentication.**

 **Strategy 2.2.H.14: Require patient authentication before operation**

 **Rationale 2.2.H.14: Substantially reduce mistakes, and inhibit deliberate misuse**

 **Trace to Requirements**

 **Requirement R7.1.0(2): Patient Authentication**

**Evidence:** ICE-PCArequirements.pdf#nameddest=patient authentication

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## Trace to Architecture



## Architecture: PCA\_Security::security.imp


**Evidence:** PCA\_Security.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## SFT: Show only authenticated patient can get infusion


**109. Claim 2.2.H.15: The use by unauthorized persons hazard has been mitigated by clinician authentication.**



 **Claim 2.2.H.15: The use by unauthorized persons hazard has been mitigated by clinician authentication.**

 **Trace mitigation to requirements, architecture, SFT**

 **Tracing is how the fact of mitigation is established**

 **Requirement: R7.1.0(1) Clinician Authentication**

 **Reference to requirements for clinician authentication**

**Evidence:** ICE-PCArequirements.pdf#nameddest=clinician authentication

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Architecture: PCA\_Security::security.imp**

 **Architecture: PCA\_Security::security.imp**

**Evidence:** PCA\_Security.aadl


**Repository:** NOR-STA SVN PCAPAC - NOR-STA

 **Trace Mitigation to Test**

 **Reference to test demonstrating mitigation**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 110. Device Hazard Analysis Guidance By FDA




 **Device Hazard Analysis Guidance By FDA**

 **Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices**

**Evidence:** FDAHazardAnalysis.pdf

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 111. Claim 2.3: Risk analysis shows fewer than one death or permanent injury in a million hours of operation due to malfunction



### Claim 2.3: Risk analysis shows fewer than one death or permanent injury in a million hours of operation due to malfunction

This claim concerns physical malfunction, including electronics and radiation effects, but not software

### Strategy 2.3: Medical device risk analyses

### FDA Guidance on Risk Analyses

FDA currently has no published guidance for risk analyses of medical devices.

The following are standard risk analyses performed by other safety-critical industries:

FHA - Functional Hazard Assessment  
FMEA - Failure Modes and Effects Analysis  
FTA - Fault Tree Analysis



## **Analyses of model apply to actual devices**

Necessarily, only models can be *analyzed*.

Consequently, the question of how accurately the model abstracts error behavior arises.



## **Functional Hazard Assessment (FHA)**

Placeholder for actual analysis.



## **Failure Modes and Effects Analysis (FMEA)**

Placeholder for actual analysis.



## **Fault Tree Analysis (FTA)**

Placeholder for actual analysis.



## **Event Tree Analysis (ETA)**


Placeholder for actual analysis.



## **System Theoretic Process Analysis (STPA)**

Placeholder for actual analysis.

## 112. Claim 2.4: Software correctly performs intended function



 **Claim 2.4: Software correctly performs intended function**

 **Transitivity**

 **Requirement -> specification -> behavior**

 **Requirements define intended function**

 **Claim 2.4.1: Software specification reflects requirements (validation)**


*See details in section 113*

 **Claim 2.4.2: Software conforms to its specification (verification)**

*See details in section 114*



### 113. Claim 2.4.1: Software specification reflects requirements (validation)




 **Claim 2.4.1: Software specification reflects requirements (validation)**

 **Validation by inspection and system feature tests**

 **Boundary of formalism must be human judged**

Software *requirements* are written in natural language of domain experts.

## 114. Claim 2.4.2: Software conforms to its specification (verification)



 **Claim 2.4.2: Software conforms to its specification (verification)**

 **Strategy 2.4.2: Use tests and formal correctness proofs to argue that software conforms to its specification**

 **Rationale 2.4.2: Tests and proofs together provide greater confidence that software meets its specification than either alone**

 **Tests can show that a tiny fraction of the overall state space is safe and effective**


 **Software Tests**

Repository: NOR-STA SVN PCAPAC - NOR-STA



**Proofs can show that the entire state space of critical software meets its specification**

## 115. Evidence



### Evidence

All evidence linked to this node



### System Feature Tests

*See details in section 116*



### Software Tests



### Hardware Tests



### Risk Analyses

FMEA, FTA, residual risk, etc.



## **Correctness Proofs**

*See details in section 117*



## **Clinical Trials**

*See details in section 118*



## **Standards and FDA Guidance**


*See details in section 119*



## **Architecture**

*See details in section 120*

## 116. System Feature Tests



### System Feature Tests

#### Basal Rate SFT

System feature test of basal rate infusion

**Evidence:** Basal Rate SFT.txt

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

**Link(s) to this node in section(s):**

Section 12. Claim 1.1.2: PCA Pump infuses at basal rate

#### Patient-Bolus Request SFT

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

**Link(s) to this node in section(s):**

Section 13. Claim 1.1.3: Upon pressing of Patient Button, a VTBI will be infused quickly, returning to basal rate

#### Clinician-Requested Bolust SFT

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

**Link(s) to this node in section(s):**

Section 14. Claim 1.1.4: Clinician may command VTBI to be infused over a specified period of time



## **Stop Infusion SFT**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

**Link(s) to this node in section(s):**

Section 15. Claim 1.1.5: Pressing Stop Button stops pumping




## **KVO or Stop on Warning or Alarm SFT**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

**Link(s) to this node in section(s):**

Section 16. Claim 1.1.6: Upon detection of minor hazards, pump at KVO rate

## 117. Correctness Proofs



### **Correctness Proofs**

#### **BLESS proof script for PCA Pump**


**Repository:** NOR-STA SVN PCAPAC - NOR-STA

#### **BLESS proof of critical thread conformance to specification**

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## 118. Clinical Trials



### Clinical Trials

Clinical trials of the intended function on patients to gauge safety and effectiveness.



### Clinical Trial Report

reference is to faux evidence that would be replaced by a real clinical trial report for a real medical device

**Evidence:** Clinical Trial Report.txt

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

**Link(s) to this node in section(s):**

Section 18. Claim 1.2: Effectiveness of intended function demonstrated in clinical trials

Section 18. Claim 1.2: Effectiveness of intended function demonstrated in clinical trials

Section 18. Claim 1.2: Effectiveness of intended function demonstrated in clinical trials



### FDA clinical trials law, regulation, and guidance

perhaps someone who knows these can add references

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

**Link(s) to this node in section(s):**

Section 18. Claim 1.2: Effectiveness of intended function demonstrated in clinical trials




### Clinical trial design documents

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

**Link(s) to this node in section(s):**

Section 18. Claim 1.2: Effectiveness of intended function demonstrated in clinical trials

## 119. Standards and FDA Guidance



### Standards and FDA Guidance

#### Total Product Life Cycle: Infusion Pump - Premarket Notification [510(k)] Submissions

**Evidence:** IPGenera Guidance.pdf


**Repository:** NOR-STA SVN PCAPAC - NOR-STA

#### Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices

**Evidence:** FDAHazardAnalysis.pdf

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## 120. Architecture





## Architecture



### PCA\_Alarm

**Evidence:** PCA\_Alarm.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### PCA\_Assertions

**Evidence:** PCA\_Assertions.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### PCA\_Boss

**Evidence:** PCA\_Boss.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### PCA\_Control\_Panel

**Evidence:** PCA\_Control\_Panel.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### PCA\_Display

**Evidence:** PCA\_Display.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### PCA\_Drug\_Library

**Evidence:** PCA\_Drug\_Library.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



### PCA\_Error\_Model

**Evidence:** PCA\_Error\_Model.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **PCA\_Fluid**

**Evidence:** PCA\_Fluid.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **PCA\_Mechanical**

**Evidence:** PCA\_Mechanical.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **PCA\_Operation**

**Evidence:** PCA\_Operation.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **PCA\_Operation\_Threads**

**Evidence:** PCA\_Operation\_Threads.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **PCA\_Power**

**Evidence:** PCA\_Power.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **PCA\_Pump**

**Evidence:** PCA\_Pump.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **PCA\_Safety**

**Evidence:** PCA\_Safety.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **PCA\_Security**

**Evidence:** PCA\_Security.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **PCA\_System**

**Evidence:** PCA\_System.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **PCA\_Types**

**Evidence:** PCA\_Types.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA



## **ICE**

**Evidence:** ICE.aadl

**Repository:** NOR-STA SVN PCAPAC - NOR-STA

## Index of assurance case components

21 CFR 880.5725 - section 6

2. Is the Software Device intended to be used in combination with a drug or biologic? Yes. - section 5

Abbreviations - section 3

Alarms can be inactivated - section 94

Alarms will be loud enough - section 94

All variables are initialized in their declaration - section 75

Analyses of model apply to actual devices - section 111

An argument that Kansas State University's Open PCA Pump design is both acceptably safe and effective - section 2

Apply criteria in Tables 1 & 2 of FDA Guidance - section 5

Architecture - section 120

Architecture: PCA\_Alarm::Flow\_Rate\_Checker.imp - section 86

Architecture: PCA\_Alarm::Flow\_Rate\_Checker.imp - section 41

Architecture: PCA\_Alarm::Flow\_Rate\_Checker.imp - section 39

Architecture: PCA\_Alarm::Flow\_Rate\_Checker.imp - section 70

Architecture: PCA\_Boss::Boss\_Thread.imp => UC1\_2\_make\_sound EC17\_audio\_fail - section 94

Architecture: PCA\_Control\_Panel::pca\_speaker - section 94

Architecture: PCA\_Control\_Panel::pca\_speaker - section 94

Architecture: PCA\_Control\_Panel::pca\_speaker - section 94

Architecture: PCA\_Control\_Panel::pca\_speaker.imp and PCA\_Control\_Panel.ui\_thread.imp - section 100

Architecture: PCA\_Control\_Panel::pca\_speaker.imp and PCA\_Control\_Panel.ui\_thread.imp - section 102

Architecture: PCA\_Control\_Panel::ui\_thread.imp - section 105

Architecture: PCA\_Control\_Panel.ui\_thread.imp - section 102

Architecture: PCA\_Drug\_Library::drug\_library\_thread.imp - section 99

Architecture: PCA\_Mechanical::scanner.imp - section 71

Architecture: PCA\_Mechanical::scanner.imp - section 83



Architecture: PCA\_Operation\_Threads::ICE\_thread.imp - section 67

Architecture: PCA\_Operation\_Threads::ICE\_thread.imp - section 74

Architecture: PCA\_Operation\_Threads::ICE\_Thread.imp - section 105

Architecture: PCA\_Operation\_Threads::ICE\_Thread.imp - section 100

Architecture: PCA\_Operation\_Threads::Patient\_Bolus\_Checker.imp - section 38

Architecture: PCA\_Operation\_Threads::Patient\_Bolus\_Checker.imp - section 106

Architecture: PCA\_Operation\_Threads::Prescription\_Checker.imp - section 99

Architecture: PCA\_Power::power\_control.imp - section 57

Architecture: PCA\_Power::power\_control.imp - section 58

Architecture: PCA\_Power::power\_control.imp - section 59

Architecture: PCA\_Power::power\_control.imp - section 60

Architecture: PCA\_Power::power\_control.imp - section 62

Architecture: PCA\_Pump::PCA\_memory.imp - section 74

Architecture: PCA\_Safety::error\_detector.imp - section 74

Architecture: PCA\_Safety::safety.imp - section 70

Architecture: PCA\_Safety::safety.imp - section 66

Architecture: PCA\_Security::Security - section 47

Architecture: PCA\_Security::Security - section 91

Architecture: PCA\_Security::Security - section 99

Architecture: PCA\_Security::Security - section 92

Architecture: PCA\_Security::security.imp - section 83

Architecture: PCA\_Security::security.imp - section 108

Architecture: PCA\_Security::security.imp - section 109

Architecture: PCA\_Security::security.imp - section 109

Architecture: PCA\_Security::security.imp - section 79

Architecture: PCA\_Security::security.imp - section 71

Architecture: PCA\_System::ice\_bus\_adaptor.imp - section 100

Architecture: PCA\_System::ice\_bus\_adaptor.imp - section 74

Argue dead users won't use PCA Pump with broken power cord again - section 85

Argue over all behaviors, that they are performed correctly, and their composition is the intended function - section 9

Argue that audible test ensures speaker works when beginning infusion, and that alarms through ICE mitigate sound failure during operation - section 84

Attestation no free flow occurs - section 35

Attestation no reverse flow occurs - section 37

Audible test ensure initially working speaker; ICE alarm mitigates failure during operation - section 84

Audible test ensures working speaker when starting infusion - section 84

Audibly sounds alarms - section 94

Audio test ensures pump can sound alarms - section 94

Background Information - section 3

Basal Rate Required - section 12

Basal Rate SFT - section 116

Basal Rate System Feature Test Report - section 12

Battery failures are detected and reported - section 60

Battery failure won't harm patient - section 45

Battery problems are detected and reported - section 59

Battery problems are detected and reported - section 58

BLESS proof of critical thread conformance to specification - section 117

BLESS proof script for PCA Pump - section 117

Both tests and analysis needed - section 35

Both tests and analysis needed - section 37

Boundary of formalism must be human judged - section 113

Can't reference the absence of something - section 75

Can't reference the absence of something - section 75

Can't reference the absence of something - section 75

Can't reference the absence of something - section 75

Certification and experience of those performing hazard analysis - section 20

Claim 0: PCA pump is effective in its medical function and is acceptably safe - section 7

Claim 1.1.1: Combination of individual behaviors is the intended function - section 10

Claim 1.1.2: PCA Pump infuses at basal rate - section 12

Claim 1.1.3: Upon pressing of Patient Button, a VTBI will be infused quickly, returning to basal rate - section 13

Claim 1.1.4: Clinician may command VTBI to be infused over a specified period of time - section 14

Claim 1.1.5: Pressing Stop Button stops pumping - section 15

Claim 1.1.6: Upon detection of minor hazards, pump at KVO rate - section 16

Claim 1.1.7: Upon detection of critical hazards, stop pumping - section 17

Claim 1.1: PCA pump performs intended function - section 9

Claim 1.2: Effectiveness of intended function demonstrated in clinical trials - section 18

Claim 1: PCA pump is effective - section 8

Claim 2.1: All hazards have been identified - section 20

Claim 2.2.A.1.1: Pump stopped when Internal air in line is detected - section 26

Claim 2.2.A.1.2: Clinician training mitigates external sources of air in line - section 28

Claim 2.2.A.1: Air in Line hazard has been mitigated - section 25

Claim 2.2.A.2.1: Occlusion is detected by up- and down-stream monitors - section 30

Claim 2.2.A.2.2: Pump stops - section 32

Claim 2.2.A.2: Occlusion hazard has been mitigated - section 29

Claim 2.2.A.3: Free flow hazard has been mitigated - section 34

Claim 2.2.A.4: Reverse flow hazard has been mitigated - section 36

Claim 2.2.A.5: Too many user boluses hazard has been mitigated - section 38

Claim 2.2.A.6: Uneven delivery hazard has been mitigated - section 39

Claim 2.2.A.7: Drug leakage hazard has been mitigated - section 40

Claim 2.2.A.8: Incorrect flow rate hazard has been mitigated - section 41

Claim 2.2: All identified hazards have been mitigated - section 21

Claim 2.2.A: Operational hazards have been mitigated - section 23

Claim 2.2.B.1: Failure to Operate due to Environment Mitigated - section 44

Claim 2.2.B.2: Pump Exposed to Pathogens, Allergens, Hazardous Substances Mitigated - section 45

Claim 2.2.B.3.1: Unauthorized tampering of pump settings mitigated - section 47

Claim 2.2.B.3.2: Panel lock broken mitigated by having strong lock and case - section 48

Claim 2.2.B.3.3: Panel/door opened during infusion mitigated by strong lock and case - section 49

Claim 2.2.B.3.4: Infusion cannot be started with open door - section 50

Claim 2.2.B.3: Tampering mitigated - section 46

Claim 2.2.B.4.1: Electromagnetic Interference Mitigated by Shielding of Case - section 52

Claim 2.2.B.4.2: Electrostatic discharge mitigated by touch-screen and case design - section 53

Claim 2.2.B.4.3: Interference from power mitigated by ferrite filter - section 54

Claim 2.2.B.4: Non-human Interference mitigated - section 51

Claim 2.2.B: Environmental hazards have been mitigated - section 42

Claim 2.2.C.1: Power supply overheating mitigated by shutting down if temperature gets too high - section 57

Claim 2.2.C.2: Backup Battery Charge Fault Mitigated by Detection and Reporting - section 58

Claim 2.2.C.3: Supply voltage error mitigated by monitoring and reporting - section 59

Claim 2.2.C.4: Battery failure mitigated by detection and reporting - section 60

Claim 2.2.C.5: Leakage current mitigated by isolating mains power - section 61

Claim 2.2.C.6: Power supply circuit failure mitigated by detection and shut off - section 62

Claim 2.2.C.7: EMI from pump mitigated by design - section 63

Claim 2.2.C: Electrical hazards have been mitigated - section 55

Claim 2.2.D.1: System Failure Mitigated by Safety Architecture - section 66

Claim 2.2.D.2: Network error mitigated by switching to stand-alone mode - section 67

Claim 2.2.D.3: Memory failure mitigated by error correction - section 68

Claim 2.2.D.4: False alarms are not hazards - section 69

Claim 2.2.D.5: Missed alarm due to sensor failure mitigated by safety architecture - section 70

Claim 2.2.D.6: Incorrect dose mitigated by Rx on label, authenticated - section 71

Claim 2.2.D: Hardware hazards have been mitigated - section 64

Claim 2.2.E.1: Data errors in event and fault logs are mitigated by fault masking and sending event reports to ICE as they occur - section 74

Claim 2.2.E.2: Software runtime errors mitigated by proving program correctness and avoiding problematic software functions - section 75

Claim 2.2.E.3: Corrupted Infusion Commands mitigated by limiting their possible function - section 76

Claim 2.2.E.4: Pump could not be silenced by alarm inactivation - section 77

Claim 2.2.E.5: Incorrect Software mitigated by version control - section 78

Claim 2.2.E.6: Incorrect drug library loaded mitigated by authentication - section 79

Claim 2.2.E.7: Failure to install software updates mitigated by manufacturer and hospital process - section 80

Claim 2.2.E: Software hazards have been mitigated - section 72

Claim 2.2.F.1: Unable to set dose mitigated by scanning Rx from label - section 83

Claim 2.2.F.2: Failure to alarm by broken speaker mitigated by alarm through ICE and audible test - section 84

Claim 2.2.F.3: Broken power cord mitigated by electrocuting users - section 85

Claim 2.2.F.4: Pump motor failure mitigated by alarm upon pump stopping - section 86

Claim 2.2.F: Mechanical hazards have been mitigated - section 81

Claim 2.2.G.1: Hazard of inadequate device cleaning mitigated by user training and certification - section 87

Claim 2.2.G.2: Hazard of contamination by blood or leaking fluid mitigated by proper cleaning - section 87

Claim 2.2.G.3: Hazard of failure to flush mitigated by control panel message reminder - section 87

Claim 2.2.G.4: Hazard of pump connected to non-sterile infusion sets mitigated by training and certification - section 87

Claim 2.2.G.5: Hazard of packaging of the pump is damaged prior to its use mitigated by receiving inspection - section 87

Claim 2.2.G.6: Hazard of patient allergy to the infusion set or infusion set adhesive by knowing allergies of patient and comparing with material of infusion set - section 87

Claim 2.2.G.7: Hazard of clinician fails to rotate infusion sites as recommended mitigated by training and certification - section 87

Claim 2.2.G.8: Hazard of chemical precipitation inside the delivery path mitigated by cleaning and material compatibility - section 87

Claim 2.2.G.9: Hazard of physical damage to pump from Inadequate device cleaning or disinfection mitigated by user training - section 87

Claim 2.2.G: Biological and chemical hazards have been mitigated - section 87

Claim 2.2.H.10: Users understand pump status and operational modes - section 105

Claim 2.2.H.11: The user's motion cause motion causes the pump to be disconnected from the user. - section 89

Claim 2.2.H.12: The self over-medication hazard has been mitigated by requiring a minimum time between patient boluses. - section 106

Claim 2.2.H.13: The clinician follows instructions to disconnect the pump - section 107

Claim 2.2.H.14: The hazard of giving the drug to the wrong patient has been mitigated by patient authentication. - section 108

Claim 2.2.H.15: The use by unauthorized persons hazard has been mitigated by clinician authentication. - section 109

Claim 2.2.H.1: The hazard of user not understanding how to initiate pump operation is mitigated by clinician authentication and training - section 91

Claim 2.2.H.2: Incorrect prescription mitigated by prescription authentication - section 92

Claim 2.2.H.3: The hazard that infusion is stopped prematurely can only be mitigated by proper procedure - section 93

Claim 2.2.H.4.1: Alarm fatigue is avoided by only raising necessary alarms - section 95

Claim 2.2.H.4.2: Background noise will not cause user(s) to fail to detect notification(s) - section 96

Claim 2.2.H.4: The hazard that the user fails to detect notifications is mitigated - section 94

Claim 2.2.H.5: The wrong drug hazard has been mitigated by authenticating Rx. - section 97

Claim 2.2.H.6: Physical set up is correct - section 98

Claim 2.2.H.7: Users cannot "work around" or "bypass" software limits on drug/dose parameters - section 99

Claim 2.2.H.8.1: False alarms/warnings are minimized to reduce alarm fatigue - section 101

Claim 2.2.H.8: The hazard that clinicians ignore warnings and alarms is mitigated - section 100

Claim 2.2.H.9.1: Standard symbols and sounds reduce misinterpretation - section 103

Claim 2.2.H.9.2: Messages are meaningful and unambiguous - section 104

Claim 2.2.H.9: Clinicians do not misinterpret alarms/warnings - section 102

Claim 2.2.H: Use hazards have been mitigated - section 89

Claim 2.3: Risk analysis shows fewer than one death or permanent injury in a million hours of operation due to malfunction - section 111

Claim 2.4.1: Software specification reflects requirements (validation) - section 113

Claim 2.4.2: Software conforms to its specification (verification) - section 114

Claim 2.4: Software correctly performs intended function - section 112

Claim 2: PCA pump is acceptably safe - section 19

Clinical trial design documents - section 118

Clinical Trial Report - section 118

Clinical Trials - section 118

Clinical trials apply the intended function - section 18

Clinical trials are well designed - section 18

Clinical trials are well executed - section 18

Clinician Authentication - section 98

Clinician manual and training ensures compatible infusion set - section 28

Clinician manual and training ensures sealed delivery path - section 28

Clinician-Requested Bolus Required - section 14

Clinician-Requested Bolus System Feature Test Report - section 14

Clinician-Requested Bolus SFT - section 116

Clinicians are authenticated before use allowed - section 98

Clinicians are authenticated before use allowed - section 91

Clinicians are properly trained - section 91

Clinicians are properly trained - section 98

Clinicians using the device must be trained; only trained clinicians may be authenticated. - section 98

Compliant with standard IEC 60601-1-2 (2001) - section 52

Compliant with standard IEC 60601-1-2 (2001) - section 63

Continuous fault detection and correction masks memory errors - section 68

Continuous fault detection and correction masks memory errors - section 74

Conventions - section 3

Correctness Proofs - section 117

Dead men infuse no drug - section 85

Definition of necessary alarm is inherently subjective, and alarm fatigue can only be judged by those who hear the alarms - section 95

Device Hazard Analysis Guidance By FDA - section 110

Diligent searching by competent professionals is the best that can be done - section 20

Divide into individual behaviors, and then argue their composition has intended function - section 9

Drug libraries are authenticated - section 79

Drug library enforces hard/soft limits - section 99

Each test adds some confidence; proof adds much confidence - section 27

Each test adds some confidence; proof adds much confidence - section 31

Each test adds some confidence; proof adds much confidence - section 33

Effect of electrostatic discharge limited - section 53

Event Tree Analysis (ETA) - section 111

Evidence - section 115

Examine variable declarations in every thread - section 75

External Infusion Pumps are FDA Class II Devices - section 6

Fact 2.2.H.10.1: Clinician focus groups understand status and modes - section 105

Fact 2.2.H.10.2: Infusion rate displayed on control panel and ICE console - section 105

Fact 2.2.H.8.1: Alarm/warning tone and volume follow IEC 60601-1-8 1.3.1 - section 100

Fact 2.2.H.8.2: Alarms/warnings sounded and displayed on control panel and ICE console - section 100

Fact 2.2.H.9.1: Alarm/warning tone and volume follow IEC 60601-1-8 1.3.1 - section 102

Fact 2.2.H.9.2.1: Clinician focus groups understand messages - section 104

Fact 2.2.H.9.2: Control panel displays helpful messages - section 102

Failure Modes and Effects Analysis (FMEA) - section 111

Fault Tree Analysis (FTA) - section 111

FDA clinical trials law, regulation, and guidance - section 118

FDA Guidance on Risk Analyses - section 111

Flow sensor failure detected and warning or alarm issued - section 70

Focus group summary - section 104



Focus group summary - section 105

Functional Hazard Assessment (FHA) - section 111

Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices - section 4

Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices - section 119

Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices - section 110

Hardware Tests - section 115

Hospital procedures for prescribing, transmitting and filling prescriptions - section 92

Hospital procedures prevent contamination - section 45

ICE - section 120

ICE commands limited to suspend and resume infusion and alarm inactivation - section 76

Individual behaviors, and intended function, as defined in Requirements - section 9

Infusion can be started only when door is closed - section 50

Intended function defined in requirements document - section 8

Issues alarms and warnings - section 94

KVO or Stop on Warning or Alarm SFT - section 116

KVO or Stop on Warning or Alarm System Feature Test Report - section 16

Labeling - section 44

Labeling - section 44

Labeling - section 44

Labeling - section 44

Labeling: Clinicians using the device must be trained; only trained clinicians may be authenticated. - section 91

Leakage current limited to 10 mA - section 61

Links to formal specification and proof - section 31

Links to formal specification and proof - section 27

Links to formal specification and proof - section 33

'Major' Level of Concern - section 4

Many other intended functions, left to reader to add to assurance case - section 9

Mechanical analysis - section 35

Mechanical analysis - section 37

Mechanical engineering analysis that free flow is impossible - section 35

Mechanical engineering analysis that reverse flow is impossible - section 37

Mitigation 2.2.H.1: Clinician authentication and clinician training - section 91

Mitigation 2.2.H.6: Physical set up, such as routing of tubing or selection of appropriate tubing set cannot be assured - section 98

No buffers are used so cannot overflow - section 75

No dynamic libraries are used so cannot be incorrect - section 75

No dynamic memory allocation or pointers are used, so the can't be null - section 75

No memory is allocated, so it can't leak - section 75

No observed free flow - section 35

No observed reverse flow - section 37

Occlusion is detected - section 30

Only authenticated prescription scanned from the drug container can be used - section 47

Opening the door when infusing raises alarm - section 50

Open PCA Pump Assurance Case - section 1

Patient bolus will not be delivered until minimum time between boluses has expired - section 38

Patient-Bolus Request Required - section 13

Patient-Bolus Request SFT - section 116

Patient-Bolus Request System Feature Test Report - section 13

Patient-Bolus Request System Feature Test Report - section 17

PCA\_Alarm - section 120

PCA\_Assertions - section 120

PCA\_Boss - section 120

PCA\_Control\_Panel - section 120

PCA\_Control\_Panel::ui\_thread - section 93

PCA\_Control\_Panel::ui\_thread - section 93

PCA\_Display - section 120

PCA\_Drug\_Library - section 120

PCA\_Error\_Model - section 120

PCA\_Fluid - section 120

PCA\_Mechanical - section 120

PCA\_Operation - section 120

PCA\_Operation\_Threads - section 120

PCA\_Power - section 120

PCA\_Pump - section 120

PCA pump act as stand-alone device when its ICE network connection fails - section 67

PCA pump has strong lock and case - section 48

PCA pump has strong lock and case - section 49

PCA Pump is Major Level of Concern as defined by FDA - section 5

PCA pump safety architecture mitigates sensor failure by monitoring and alarm if failed - section 70

PCA pump safety architecture mitigates system failure - section 66

PCA\_Safety - section 120

PCA\_Security - section 120

PCA\_Security::security - section 97

PCA\_Security::Security - section 98

PCA\_System - section 120

PCA\_Types - section 120

Pharmacist education, training, and judgement - section 92

Pharmacy fills prescription correctly, and attaches correct label - section 92

Physician education, experience, and judgement - section 92

Physician prescribes correctly - section 92

Prescription Authentication Test - section 97

Prescriptions are authenticated - section 99

Prescriptions are read from drug container and authenticated - section 47

Prescriptions are read from drug container and authenticated - section 92

Prescriptions are scanned from drug label - section 71

Prescriptions are scanned from drug label - section 83

Proofs can show that the entire state space of critical software meets its specification - section 114

Pump can only be operated by authenticated clinician - section 98

Pump KVO upon minor hazard Required - section 16

Pump minimizes drug leakage - section 40

Power interference limited by ferrite filter - section 54

Rationale 0: No medical device can be completely safe; its benefit must justify its risk - section 7

Rationale 1.1.1: Requirement define intended function, tracing behavior to requirements shows it's part of the intended function - section 10

Rationale 1.1.2: SFT is direct confirmation of behavior defined in requirement - section 12

Rationale 1.1.3: SFT is direct confirmation of behavior defined in requirement - section 13

Rationale 1.1.4: SFT is direct confirmation of behavior defined in requirement - section 14

Rationale 1.1.5: SFT is direct confirmation of behavior defined in requirement - section 15

Rationale 1.1.6: SFT is direct confirmation of behavior defined in requirement - section 16

Rationale 1.1.7: SFT is direct confirmation of behavior defined in requirement - section 17

Rationale 1: PCA pump must perform intended function; that function must be medically effective - section 8

Rationale 2.2.A.1: Mitigations of external and internal hazards differ - section 25

Rationale 2.2.A.5: Enforcing minimum time between boluses prevents too many user boluses - section 38

Rationale 2.2.A.6: Alarming when upon uneven delivery stops flow and hails clinician - section 39

Rationale 2.2.A.7: Mechanical engineers should be able to design pumps that don't leak by now - section 40

Rationale 2.2.A.8: Alarming when upon uneven delivery stops flow and hails clinician - section 41

Rationale 2.2.A: Mitigation of each hazard adds confidence to safety - section 23

Rationale 2.2.B.1: Restricting to environments for which the device was designed mitigates environmental effects - section 44

Rationale 2.2.B.2: Prevent exposure and limiting battery leakage mitigates hazardous substances - section 45

Rationale 2.2.B.3.1: Can't tamper what can't be changed - section 47

Rationale 2.2.B.3.2: Strong lock and case is hard to break - section 48

Rationale 2.2.B.3.3: Strong lock and case makes door hard to open inappropriately - section 49

Rationale 2.2.B.3.4: Tempering is difficult when the door is closed - section 50

Rationale 2.2.B.3: Must mitigate each different kind of tampering - section 46

Rationale 2.2.B.4.1: Shielding mitigates electrical interference - section 52

Rationale 2.2.B.4.2: Reducing effects of electrostatic discharge mitigate interference - section 53

Rationale 2.2.B.4.3: Reducing interference from power mitigates interference - section 54

Rationale 2.2.B.4: Electromagnetic compatibility mitigates interference - section 51

Rationale 2.2.B: Mitigation of each environmental hazard adds confidence to safety - section 42

Rationale 2.2.C.1: Let it fail and switch to battery backup - section 57

Rationale 2.2.C.2: Detecting and reporting battery problems mitigates their effect - section 58

Rationale 2.2.C.3: Detecting and reporting power supply voltage out-of-range mitigates their effect - section 59

Rationale 2.2.C.4: Detecting and reporting battery failures mitigates their effect - section 60

Rationale 2.2.C.5: Limiting leakage current mitigates its hazard - section 61

Rationale 2.2.C.6: Let it fail and switch to battery backup - section 62

Rationale 2.2.C.7: Shielding mitigates electrical interference - section 63

Rationale 2.2.C: Mitigation of each hazard adds confidence to safety - section 55

Rationale 2.2.D.1: Separate safety architecture detects and mitigates faults in operation - section 66

Rationale 2.2.D.2: Switching from ICE to stand alone is always safe - section 67

Rationale 2.2.D.3: Error correction masks some memory errors - section 68

Rationale 2.2.D.4: False alarms are annoying, and may cause alarm fatigue, but are not themselves hazards - section 69

Rationale 2.2.D.5: Separate safety architecture detects and mitigates sensor failure by continuously monitoring sensors and sounding alarm upon failure - section 70

Rationale 2.2.D.6: Scanning prescription avoids entry errors; authentication mitigates hazard the label is mis-read - section 71

Rationale 2.2.D: Mitigation of each hazard adds confidence to safety - section 64

Rationale 2.2.E.1: Memory error correction masks many data errors, sending event to ICE as they occur provides redundant backup - section 74

Rationale 2.2.E.2: Avoiding problematic software function prevents problems from them and that correctness proof enhance confidence that software meets its specification - section 75

Rationale 2.2.E.3: ICE can only suspend and resume infusion or inactivate alarms which cannot cause harm - section 76

Rationale 2.2.E.4: Throwing the alarming device out the window may not silence alarms, but you won't hear it so loudly any more - section 77

Rationale 2.2.E.5: FDA Quality System Regulation requires proper version control - section 78

Rationale 2.2.E.6: Drug library authentication makes it difficult to install an incorrect drug library - section 79

Rationale 2.2.E.7: FDA Quality System Regulation requires proper version control - section 80

Rationale 2.2.E: Mitigation of each hazard adds confidence to safety - section 72

Rationale 2.2.F.1: Scanning prescription avoids entry errors; authentication mitigates hazard the label is mis-read - section 83

Rationale 2.2.F.5: When notified of pump failure by alarm, clinician can substitute working pump - section 86

Rationale 2.2.F: Mitigation of each hazard adds confidence to safety - section 81

Rationale 2.2.G: These are mostly 'wet' safety hazards, or material issues unrelated to system design - section 87

Rationale 2.2.H.10: Asking users is the only way to assess understanding - section 105

Rationale 2.2.H.13: Wet safety that cannot be accomplished by pump (Use Case 1 step 17) - section 107

Rationale 2.2.H.14: Substantially reduce mistakes, and inhibit deliberate misuse - section 108

Rationale 2.2.H.1: Authentication prevents use by untrained persons - section 91

Rationale 2.2.H.2: Reading Rx from drug container precludes mistakes in entry, and authentication precludes deliberate mis-entry - section 92

Rationale 2.2.H.3: Necessity to allow halting of infusion when (possibly) unsafe makes the risk that infusion is stopped prematurely unpreventable - section 93

Rationale 2.2.H.4.2: This claim is unverifiable - section 96

Rationale 2.2.H.4: To detect audible notification they must be heard and not ignored - section 94

Rationale 2.2.H.6: Clinicians administering PCA must do it right; nothing in pump design can help - section 98

Rationale 2.2.H.7: PCA Pump features prevent anything other than correct prescription use - section 99

Rationale 2.2.H.8.1: This is 'wet' safety - section 101

Rationale 2.2.H.8: Loud, distinctive alarms/warnings are hard to ignore, minimizing false alarms reduces alarm fatigue, redundant alarms make it more likely that someone will hear/see them - section 100

Rationale 2.2.H.9.1: Presume that standard sounds and symbols are commonly, and unambiguously understood - section 103

Rationale 2.2.H.9.2: Asking users is the only way to assess understanding - section 104

Rationale 2.2.H.9: Standard symbols are commonly understood; meaningful, unambiguous messages are understood - section 102

Rationale 2.2.H: Mitigation of each hazard adds confidence to safety - section 89

Rationale 2.2: Mitigation of each hazard adds confidence of safety - section 22

Rationale 2.4.2: Tests and proofs together provide greater confidence that software meets its specification than either alone - section 114

Rationale 4: Valid clinical trials must apply the intended function, and show it's acceptably safe - section 18

Redundant alarm when connected to ICE - section 84

Reference to AADL architecture component - section 32

Reference to AADL architecture component - section 26

Reference to AADL architecture component - section 30

Reference to another test demonstrating mitigation - section 31

Reference to another test demonstrating mitigation - section 33

Reference to another test demonstrating mitigation - section 27

Reference to clinician manual - section 28

Reference to clinician manual - section 28

Reference to requirements for clinician authentication - section 109

Reference to requirements for mitigation - section 30

Reference to requirements for mitigation - section 36

Reference to requirements for mitigation - section 34

Reference to requirements for mitigation - section 32

Reference to requirements for mitigation - section 34

Reference to requirements for mitigation - section 26

Reference to requirements for mitigation - section 36

Reference to test demonstrating mitigation - section 31

Reference to test demonstrating mitigation - section 33

Reference to test demonstrating mitigation - section 109

Reference to test demonstrating mitigation - section 27

Rely on mechanical design of pumping mechanism - section 34

Rely on mechanical design of pumping mechanism - section 36

Report on process of hazard elicitation - section 20

Requirement 7.1.0(3) Prescription Authentication - section 97

Requirement R2.4.0(1) Temperature Range - section 44

Requirement R2.4.0(2) Atmospheric Pressure - section 44

Requirement R2.4.0(3) Relative Humidity - section 44

Requirement R2.4.0(4) Splashing - section 44

Requirement: R4.1.0(1) Basal Flow Rate - section 12

Requirement: R4.1.0(4) Alarm Stops Basal Rate - section 17

Requirement: R4.1.0(4) Alarm Stops Basal Rate - section 16

Requirement: R4.2.0(1) Patient-Requested Bolus - section 13

Requirement R4.2.0(3): Minimum time between patient-requested bolus - section 38

Requirement R4.2.0(3): Minimum Time Between Patient-Requested Bolus - section 106

Requirement: R4.2.0(6) Alarm Stops Patient-Reqested Bolus - section 16

Requirement: R4.2.0(6) Alarm Stops Patient-Reqested Bolus - section 17

Requirement: R4.3.0(2) - section 14

Requirement: R4.3.0(4) Alarm Halts Clinician-Reqested Bolus - section 17

Requirement: R4.3.0(4) Alarm Halts Clinician-Reqested Bolus - section 16



Requirement R5.1.0(3) Scan Drug's Package Label - section 71

Requirement R5.1.0(3) Scan Drug's Package Label - section 83

Requirement R5.4.0(1) Issue Alarms and Warnings - section 94

Requirement R5.4.0(2) Basal Over-Infusion Alarm - section 70

Requirement R5.4.0(2) Basal Over-Infusion Alarm - section 41

Requirement R5.4.0(2) Basal Over-Infusion Alarm - section 39

Requirement R5.4.0(3) Basal Under-Infusion Warning - section 70

Requirement R5.4.0(3) Basal Under-Infusion Warning - section 41

Requirement R5.4.0(3) Basal Under-Infusion Warning - section 86

Requirement R5.4.0(3) Basal Under-Infusion Warning - section 39

Requirement R5.4.0(4) Bolus Over-Infusion Alarm - section 41

Requirement R5.4.0(4) Bolus Over-Infusion Alarm - section 39

Requirement R5.4.0(4) Bolus Over-Infusion Alarm - section 70

Requirement R5.4.0(5): Bolus Under-Infusion Warning - section 41

Requirement R5.4.0(5): Bolus Under-Infusion Warning - section 70

Requirement R5.4.0(5): Bolus Under-Infusion Warning - section 39

Requirement R5.4.0(5): Bolus Under-Infusion Warning - section 86

Requirement R5.4.0(6): Square Bolus Over-Infusion Alarm - section 39

Requirement R5.4.0(6): Square Bolus Over-Infusion Alarm - section 70

Requirement R5.4.0(6): Square Bolus Over-Infusion Alarm - section 41

Requirement R5.4.0(7) Square Bolus Under-Infusion Warning - section 41

Requirement R5.4.0(7) Square Bolus Under-Infusion Warning - section 86

Requirement R5.4.0(7) Square Bolus Under-Infusion Warning - section 39

Requirement R5.4.0(7) Square Bolus Under-Infusion Warning - section 70

Requirement R5.4.3(1) Alarm Melody - section 100

Requirement R5.4.3(1) Alarm Melody - section 102

Requirement R5.4.3(1) Audible Alarm Signals - section 102

Requirement R5.4.3(1) Audible Alarm Signals - section 100

Requirement R5.4.3(2) Auditory Volume - section 94

Requirement R5.4.3(2) Auditory Volume - section 102

Requirement R5.4.3(2) Auditory Volume - section 100

Requirement R5.5.0(12) Sound Alarm - section 94

Requirement R5.5.0(19) Confirm Sound of Audible Alarm - section 84

Requirement R.5.5.0(19) Sound of Audible Alarm Test - section 94

Requirement R5.5.0(22): Resume Infusion - section 93

Requirement R5.5.0(23): Display Infusion Rate - section 105

Requirement R5.5.0(2): Start Button - section 93

Requirement R5.5.0(4) Helpful messages - section 102

Requirement R5.5.0(6): Stop Button - section 93

Requirement: R5.5.0(6) Stop Infusion - section 15

Requirement R5.5.0(7): Stop Infusion - section 93

Requirement R5.7.0(1): ICE Operating Status - section 105

Requirement R5.7.0(2): ICE alarms - section 84

Requirement R5.7.0(2): ICE Alarms - section 100

Requirement: R5.7.0(2) ICE Alarms - section 74

Requirement: R5.7.0(4) ICE KVO Rate - section 76

Requirement: R5.7.0(5) ICE Resume Infusion - section 76

Requirement: R5.7.0(7) ICE Inactivate Alarms - section 76

Requirement R5.9.0(3): Drug Library Checking - section 99

Requirement R6.1.0(1) Safety Architecture - section 66

Requirement R6.1.0(1) Safety Architecture - section 70

Requirement R6.1.0(1) Safety Architecture - section 70

Requirement R6.2.0(4) Upstream Occlusion Alarm - section 70

Requirement R6.2.0(5) Downstream Occlusion Alarm - section 70

Requirement R6.2.0(8) Open Door Alarm - section 50

Requirement R6.3.0(10): Electrostatic Discharge - section 53

Requirement R6.3.0(11): Filter Power Interference - section 54

Requirement R6.3.0(1) Battery Backup - section 62

Requirement R6.3.0(1) Battery Backup - section 57

Requirement R6.3.0(4) Low-Battery Warning - section 58

Requirement R6.3.0(5) Battery Failure Alarm - section 60

Requirement R6.3.0(5) Battery Failure Alarm - section 58

Requirement R6.3.0(6) Voltage Out-Of-Range Warning - section 59

Requirement R6.3.0(7) Leakage Current - section 61

Requirement R6.3.0(8) Component Failure - section 45

Requirement R6.3.0(9) Electromagnetically Compatible - section 52

Requirement R6.3.0(9) Electromagnetically Compatible - section 63

Requirement: R6.4.0(3) Continuous Fault-Detection - section 68

Requirement: R6.4.0(3) Continuous Fault-Detection - section 74

Requirement: R6.4.0(4) Single-Event Upsets - section 74

Requirement: R6.4.0(4) Single-Event Upsets - section 68

Requirement: R6.4.0(5) Masked Faults - section 74

Requirement: R6.4.0(5) Masked Faults - section 68

Requirement: R6.4.0(6) Hardware Detected Faults - section 68

Requirement: R6.4.0(6) Hardware Detected Faults - section 74

Requirement R6.5.0(1) Tamper-Resistant Door - section 48

Requirement R6.5.0(1) Tamper-Resistant Door - section 49

Requirement R6.5.0(2) Door Closed and Locked - section 50

Requirement R6.5.0(4) Pump Case - section 48

Requirement R6.5.0(4) Pump Case - section 49

Requirement R6.7.0(1) Minimize Drug Leakage - section 40

Requirement R7.1.0(1): Clinician Authentication - section 91

Requirement: R7.1.0(1) Clinician Authentication - section 109

Requirement R7.1.0(2): Patient Authentication - section 108

Requirement R7.1.0(3) Prescription Authentication - section 71

Requirement R7.1.0(3) Prescription Authentication - section 83

Requirement R7.1.0(3): Prescription Authentication - section 47

Requirement R7.1.0(3): Prescription Authentication - section 92

Requirement R7.1.0(3): Prescription Authentication - section 99

Requirement: R7.1.0(4) Drug Library Authentication - section 79

Requirement R7.5.0(6) Stand-Alone - section 67

Requirements define intended function - section 112

Requirements: Draft 0.11 - section 2

Requirement -> specification -> behavior - section 112

Requirements: R4.4.0(14) Inactivate Audible Alarms Indefinitely - section 94

Requirements: R4.4.0(15) Inactivate Audible Alarms Temporarily - section 94

Requirements Reference - section 11

Restricted Atmospheric Pressure - section 44

Restricted Relative Humidity - section 44

Restricted temperature range - section 44

Results of clinical trials show intended function had intended effect - section 18

Risk Analyses - section 115

Sending events to ICE provides another copy of data if corrupted or lost in device - section 74

SFT 2.2.H.2: Only authenticated prescription scanned from the drug container can be used - section 92

SFT: Alarms/warning relayed to ICE console - section 100

SFT: artificially force pump stoppage, check for warning(s) - section 86

SFT: Attempt to press patient button before minimum time between boluses expires - section 38

SFT: Check that infusion rate/operating status displayed on control panel and ICE console - section 105

SFT: Drug library is accessed for drug prescribed and hard/soft limits checked - section 99

SFT: Force variance of flow rate, check if appropriate alarm or warning is railed - section 41

SFT: Force variance of flow rate, check if appropriate alarm or warning is railed - section 39

SFT: Force variance of flow rate, check if appropriate alarm or warning is raised - section 70

SFT: Measure alarm/warning volume and tone - section 100

SFT: Measure alarm/warning volume and tone - section 102

SFT: Only authenticated prescription scanned from the drug container can be used - section 99

SFT: read prescription from label, check authentication - section 83

SFT: read prescription from label, check authentication - section 71

SFT: Show only authenticated patient can get infusion - section 108

SFT: Show that no patient bolus delivered before minimum time between bolus - section 106

SFT: Verify helpful messages - section 102

Software Tests - section 114

Software Tests - section 115

Splashing Resistance - section 44

Standards and FDA guidance - section 20

Standards and FDA Guidance - section 119

Start button resumes infusion - section 93

Stop button halts infusion - section 93

Stop Button Halts Infusion Required - section 15

Stop Infusion SFT - section 116

Stop Infusion System Feature Test Report - section 15

Stop on Critical Hazard Required - section 17

Stopping pump upon occlusion is safe - section 29

Strategy 0: Argue for safety and effectiveness separately, but coordinated - section 7

Strategy 1.1.1: Claimed behaviors are traced to Requirements - section 10

Strategy 1.1.2: Trace to Requirement and System Feature Test - section 12

Strategy 1.1.3: Trace to Requirement and System Feature Test - section 13

Strategy 1.1.4: Trace to Requirement and System Feature Test - section 14

Strategy 1.1.5: Trace to Requirement and System Feature Test - section 15

Strategy 1.1.6: Trace to Requirement and System Feature Test - section 16

Strategy 1.1.7: Trace to Requirement and System Feature Test - section 17

Strategy 1.2: Clinical trials must be well designed, well executed, the intended function performed, and results are acceptably safe - section 18

Strategy 1: PCA pump performs intended function which has been clinically verified - section 8

Strategy 2.1: Diligent searching by competent professionals for all possible hazards - section 20

Strategy 2.2.A.1.1: Stopping pump prevents air in line from entering patient - section 26

Strategy 2.2.A.1.2: Rely on training because pump cannot detect external air in line - section 28

Strategy 2.2.A.1: Argue for mitigation of internal and external causes of air in line separately - section 25

Strategy 2.2.A.2.2: Pump stops when commanded to do so - section 32

Strategy 2.2.A.2: Detect occlusion; stop pump - section 29

Strategy 2.2.A.3: Show pump is incapable of free-flow - section 34

Strategy 2.2.A.4: Show pump is incapable of reverse flow - section 36

Strategy 2.2.A.5: Show minimum time between patient-requested boluses - section 38

Strategy 2.2.A.6: Measure drug flow and alarm if measurement differs from intended pump rate by more than allowed tolerance - section 39

Strategy 2.2.A.7: Argue drug leakage minimized by competent mechanical engineering - section 40

Strategy 2.2.A.8: Measure drug flow and alarm if measurement differs from intended pump rate by more than allowed tolerance - section 41

Strategy 2.2.A Induction over operational hazards - section 23

Strategy 2.2.B.1: Restrict operation to safe environments - section 44

Strategy 2.2.B.2: Don't expose to hazardous substances, limit battery leakage - section 45

Strategy 2.2.B.3.1: Pump setting can only be read from authenticated prescription on drug container label - section 47

Strategy 2.2.B.3.2: Argue strong lock and case mitigates breakage - section 48

Strategy 2.2.B.3.3: Argue strong lock and case mitigates door opening - section 49

Strategy 2.2.B.3.4: Argue that requiring the door to be closed makes tampering difficult - section 50

Strategy 2.2.B.3: Show tampering mitigated by pump features - section 46

Strategy 2.2.B.4.1: Argue shielding mitigates electrical interference - section 52

Strategy 2.2.B.4.2: Argue reducing effects of electrostatic discharge mitigate interference - section 53

Strategy 2.2.B.4.3: Argue reducing interference from power mitigates interference - section 54

Strategy 2.2.B.4: Mandate electromagnetic compatibility and non-interference - section 51

Strategy 2.2.B: Induction over environmental hazards - section 42

Strategy 2.2.C.1: No power supply overheating detection - section 57

Strategy 2.2.C.2: Detect and report battery failure and low battery voltage - section 58

Strategy 2.2.C.3: Detect and report power supply voltage out-of-range - section 59

Strategy 2.2.C.4: Detect and report battery failure - section 60

Strategy 2.2.C.5: Limit leakage current - section 61

Strategy 2.2.C.6: No power supply circuit failure detection - section 62

Strategy 2.2.C.7: Argue shielding mitigates electrical interference - section 63

Strategy 2.2.C: Induction over electrical hazards - section 55

Strategy 2.2.D.1: Argue that separate safety architecture detects and mitigates faults in operation - section 66

Strategy 2.2.D.2: Argue that switching from ICE to stand alone is always safe - section 67

Strategy 2.2.D.3: Argue that error correction masks some memory errors - section 68

Strategy 2.2.D.4: Argue that false alarms are not hazards - section 69

Strategy 2.2.D.5: Argue that separate safety architecture detects and mitigates sensor failure - section 70

Strategy 2.2.D.6: Scanning and authenticating the prescription from the label on the drug container obviates many mechanical and use hazards - section 71

Strategy 2.2.D: Induction over hardware hazards - section 64

Strategy 2.2.E.1: Argue fault masking and redundant recording mitigate data errors - section 74

Strategy 2.2.E.2: Argue avoiding problematic software function prevents problems from them and that correctness proof enhance confidence that software meets its specification - section 75

Strategy 2.2.E.3: Argue limiting ICE commands to safe operations precludes their corruption - section 76

Strategy 2.2.E.4: Unplug pump from power, and defenestrate it - section 77

Strategy 2.2.E.5: Proper version control prevents incorrect software versions or updates to be fielded - section 78

Strategy 2.2.E.6: Argue that drug library authentication mitigates mistakes and deliberate forgery - section 79

Strategy 2.2.E.7: Proper version control prevents incorrect software versions or updates to be fielded - section 80

Strategy 2.2.E: Induction over software hazards - section 72

Strategy 2.2.F.1: Scanning and authenticating the prescription from the label on the drug container obviates many mechanical and use hazards - section 83

Strategy 2.2.F.5 Argue that alarm mitigates failure - section 86

Strategy 2.2.F: Induction over mechanical hazards - section 81

Strategy 2.2.G: Biological and chemical hazards are mitigated by using biocompatible materials, and proper procedure - section 87

Strategy 2.2.H.10: Test focus group of clinicians for their understanding of status and modes - section 105

Strategy 2.2.H.13: Clinician training to disconnect pump - section 107

Strategy 2.2.H.14: Require patient authentication before operation - section 108

Strategy 2.2.H.1: This is an unverifiable claim - section 95

Strategy 2.2.H.2: Having prescription electronically read from drug container, and authenticated ensures the prescription from the pharmacy is used during operation - section 92

Strategy 2.2.H.3: Anyone can press the Stop Button to halt infusion - section 93

Strategy 2.2.H.4.2: Background noise is a function of place of use - section 96

Strategy 2.2.H.4: Pump makes audible alarms, which are heard by clinician(s), and not ignored - section 94

Strategy 2.2.H.7: Authenticated prescription and drug library hard/soft limits preclude work arounds - section 99

Strategy 2.2.H.8.1: No way to verify that alarms/warnings are minimized, or that alarm fatigue is reduced. - section 101

Strategy 2.2.H.8: Make alarms/warnings loud, distinctive, and redundant - section 100

Strategy 2.2.H.9.1: Make unsupported claim - section 103

Strategy 2.2.H.9.2: Test focus group of clinicians for their understanding of messages - section 104

Strategy 2.2.H.9: Use standard symbols and sounds; meaningful, unambiguous messages - section 102



Strategy 2.2.H: Induction over use hazards - section 89

Strategy 2.2: Induction over all identified hazards, by class of hazard - section 21

Strategy 2.3: Medical device risk analyses - section 111

Strategy 2.4.2: Use tests and formal correctness proofs to argue that software conforms to its specification - section 114

Strategy 2: Residue risk of potential hazards after mitigations is acceptable considering the therapeutic value of its intended function - section 19

Subjective argument about the value of pain relief - section 19

Subject of Assurance Case: PCA Pump - section 2

Switch to battery backup upon power supply failure - section 62

Switch to battery backup upon power supply failure - section 57

System Feature Tests - section 116

System Feature Test: Pump can only be operated by authenticated clinician - section 91

System Theoretic Process Analysis (STPA) - section 111

Table 1 – Operational Hazard Examples - section 24

Table 1 – Operational Hazard Examples - section 24

Table 2 – Environmental Hazard Examples - section 43

Table 2 – Environmental Hazard Examples - section 43

Table 3 – Electrical Hazard Examples - section 56

Table 3 – Electrical Hazard Examples - section 56

Table 4 – Hardware Hazard Examples - section 65

Table 4 – Hardware Hazard Examples - section 65

Table 5 – Software Hazard Examples - section 73

Table 5 – Software Hazard Examples - section 73

Table 6 – Mechanical Hazard Examples - section 82

Table 6 – Mechanical Hazard Examples - section 82

Table 7 – Biological and Chemical Hazard Examples - section 88

Table 7 – Biological and Chemical Hazard Examples - section 88

Table 8 – Use Hazard Examples - section 90

Table 8 – UsewHazard Examples - section 90

Tests and mechanical analysis - section 37

Tests and mechanical analysis - section 35

Tests and Proof - section 31

Tests and Proof - section 33

Tests and Proof - section 27

Tests can show that a tiny fraction of the overall state space is safe and effective - section 114

Theraputic value justifies risk - section 19

The Requirements define intended function - section 10

Total Product Life Cycle: Infusion Pump - Premarket Notification [510(k)] Submissions - section 119

Trace mitigation to architecture - section 30

Trace mitigation to architecture - section 32

Trace mitigation to architecture - section 26

Trace Mitigation to Architecture - section 106

Trace Mitigation to Architecture - section 97

Trace mitigation to mechanical pump design - section 34

Trace mitigation to mechanical pump design - section 36

Trace mitigation to requirements - section 30

Trace mitigation to requirements - section 26

Trace mitigation to requirements - section 34

Trace mitigation to requirements - section 32

Trace mitigation to requirements - section 36

Trace Mitigation to Requirements - section 106

Trace Mitigation to Requirements - section 97

Trace mitigation to requirements, architecture, and verification artifacts - section 32

Trace mitigation to requirements, architecture, and verification artifacts - section 26

Trace mitigation to requirements, architecture, and verification artifacts - section 30

Trace mitigation to requirements, architecture, SFT - section 106

Trace mitigation to requirements, architecture, SFT - section 109

Trace mitigation to requirements, architecture, SFT - section 97

Trace mitigation to software correctness proof - section 31

Trace mitigation to software correctness proof - section 33

Trace mitigation to software correctness proof - section 27

Trace Mitigation to Test - section 106

Trace Mitigation to Test - section 97

Trace Mitigation to Test - section 109

Trace mitigation to testing - section 27

Trace mitigation to testing - section 33

Trace mitigation to testing - section 31

Trace to Architecture - section 108

Trace to Requirements - section 108

Tracing is how the fact of mitigation is established - section 109

Tracing is how the fact of mitigation is established - section 106

Tracing is how the fact of mitigation is established - section 97

Training mitigates external sources of air in line - section 28

Transitivity - section 112

TRUST-IT assurance case notation - section 3

Under-infusion warning when pump stops - section 86

Uneven delivery detected and warning or alarm issued - section 41

Uneven delivery detected and warning or alarm issued - section 39

Untitled argumentation strategy - section 22

Untitled rationale - section 22

Used properly by trained clinicians - section 19

Validation by inspection and system feature tests - section 113

Verification of mitigation - section 31

Verification of mitigation - section 27

Verification of mitigation - section 33

Verification of Mitigation - section 37

Verification of Mitigation - section 35

Version control is a business process issue (wet safety) that cannot be mitigated by device design - section 78

Version control is a business process issue (wet safety) that cannot be mitigated by device design - section 80

Wet safety - section 45

'Wet' Safety vs. 'Dry' Safety - section 3